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1.1 Introduction 
 
 
The emergence of drug-resistant strains of pathogenic bacteria, fungi and 
protozoans requires a consistent effort from scientists worldwide in developing new 
drugs. The cell wall core of these pathogens is composed of several different 
glycoconjugate structures, lipids and polysaccharides; essential for the cell wall rigidity, 
adhesion to mammalian host and pathogen-host interactions. Among these components is 
the monosaccharide galactofuranose (Galf) present in abundance in opportunistic fungi, 
Aspergillus fumigatus and protozoan parasites such as Trypanosoma cruzi and 
Leishmania major1.  
UDP-galactopyranose mutase (UGM) is a central enzyme involved in the 
biosynthesis of galactofuranose in these pathogens2.  UGM is an atypical flavoenzyme 
that catalyzes the interconversion between UDP-galactopyranose (UDP-Galp) and UDP-
galactofuranose (UDP-Galf) (Fig. 1.1). Flavoenzymes are typically known to catalyze 
redox reactions, but UGM (although active in its reduced state) catalyzes the reaction 
without any net transfer of electrons.  
 
          
 
         Fig. 1.1 Reaction catalyzed by UGM. 
 
Bacterial UGMs from Escherichia coli3, Mycobacterium tuberculosis4 and 
Klebsiella pneumoniae4b have been somewhat characterized in detail using structural and 
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biochemical methods, but major questions about the catalytic and structural properties of 
eukaryotic UGMs remain unanswered. Furthermore, eukaryotic UGMs share only ~15 % 
sequence homology with prokaryotic UGMs. Thus, the unique chemistry of UGMs and 
its implication in the virulence of pathogenic bacteria, fungi and protozoans make it a 
potential drug target5. 
 
1.1 Biosynthesis of Galactofuranose 
 
 Galactofuranose (Galf) is the five-membered ring form of galactose present in 
most microbial pathogens and lower eukaryotes. All mammals have this sugar, but only 
in the six-membered pyranose ring form. Several enzymes are involved in the 
biosynthesis of Galf and its transport to different cell wall and extracellular structures of 
pathogenic bacteria, fungi and protozoans (Fig. 1.2). The major component involved in 
the biosynthesis of galactofuranose is UDP-Galf, the only known donor of Galf in these 
pathogens. 
           
        Fig. 1.2 Schematic of enzymes involved in Galactofuranose biosynthetic pathway. 
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1.2.1 UDP-Glucose-4’-epimerase (GalE) 
 The first enzyme required for Galf biosynthesis is UDP-glucose-4’-epimerase 
(GalE) that catalyzes the reversible reaction between UDP-glucopyranose (UDP-Glcp) 
and UDP-galactopyranose (UDP-Galp). In T. cruzi, GalE metabolism is important for the 
survival of the parasite6. Several inhibitors have been identified against this enzyme but 
due to the presence of GalE homolog in humans, it poses toxic side effects. On the 
contrary, in L. major, galactose can be obtained from the environment and studies have 
shown that enzymes involved in the synthesis of GalE are not essential for the survival of 
Leishmania spp.7 
 
1.2.2 UDP-Galactopyranose mutase (UGM) 
 UGM catalyzes the interconversion between UDP-Galp and UDP-Galf. It is the 
sole biological source of UDP-Galf and is absent in humans thus, an ideal drug target. 
Moreover, deletion of the gene-encoding UGM (glf) in L. major shows that it is essential 
for its survival and pathogenesis5a. Previous studies have also shown that Galf is a 
virulence factor in the pathogenic fungus Aspergillus fumigatus5b. 
 
1.2.3 UDP-Galf transporters 
 The product of UGM catalysis, UDP-α-Galf is transported from cytosol to the 
lumen of Golgi body by the enzyme, UDP-Galf transporter for galactofuranosylation of 
glycoproteins and glycolipids in the cell wall structures. These enzymes are not very well 
characterized until recently, the first UDP-Galf transporter specific for UDP-Galf was 
identified in Aspergillus fumigatus8.  
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1.2.4 UDP- Galactofuranose transferases (GalfT) 
 Finally, another enzyme directly involved in Galf metabolism is 
Galactofuranosyltransferase that transfers Galf to various glycoconjugate structures 
present at the cell surface or extracellular matrix. Among these enzymes is LPG-1, that 
has been extensively studied in L. major and is responsible for the addition of Galf to 
lipophosphoglycans (LPG), but not glycoinositolphospholipids (GIPLs)9. Sequence 
alignment results have shown that more than 30 GalfTs are present in T. cruzi that share 
significance sequence homology with L. major LPG110. Due to the large number of 
putative GalfTs reported in T. cruzi, targeting this enzyme might not be an effective 
strategy.  
 Therefore, UGM is a central enzyme involved in Galf biosynthesis and thus, a 
potential drug target.                   
 
1.2 Role of galactofuranose in eukaryotic UGMs 
1.2.1 Role of Galf in the pathogenesis of Aspergillus fumigatus 
 
Aspergillus fumigatus is the cause of invasive aspergillosis (IA) and 
bronchopulmonary aspergillosis (BPA) in immunocompromised individuals. The overall 
mortality rates associated with IA are > 50 % and as high as 95 % in certain cases11. Over 
10 % of the patients receiving bone marrow transplantation develop invasive aspergillosis 
during clinical treatment12. Despite the use of antifungal agents in treating aspergillosis, 
overall mortality rate associated with IA remains high13. This suggests that new 
antifungal agents and co-therapies are needed for treating aspergillosis.  
The cell wall of A. fumigatus is composed of galactomannan residues consisting 
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of a linear mannan core branched with galactofuranose side chains (Fig. 1.3). The 
deletion of the gene-encoding UGM (glf) results in a decreased cell wall thickness of A. 
fumigatus, thus making it more susceptible to antifungal drugs2a, 5b. Also, tests for 
pathogenecity in a low-dose mouse model of IA have shown that Δglf mutant has an 
attenuated virulence as compared to those inflicted with the wt5b. Thus, the decreased 
virulence and increased susceptibility to antifungal drugs make UGM a potential drug 
target for treating aspergillosis. 
 
     
 
Fig. 1.3 Different Galf containing glycoconjugates found in (A) Aspergillus spp. and (B) protozoans2b. 
 
1.2.1 Role of Galf in the pathogenesis of Leishmania major 
 Leishmania major is the cause of cutaneous and lethal visceral leishmaniasis; not 
only in tropical and mediterranean regions of Africa, India, Middle East and Asia, but 
also in parts of Southern Europe14. Leishmania parasite is transmitted to humans by 
female sandfly bite and causes the third most important vector-borne disease after malaria 
and African trypanosomiasis15. Approximately 58,000 cases of visceral leishmaniasis and 
220,000 cases of cutaneous leishmaniasis are reported officially each year16. Current 
treatments use pentavalent antimony compounds that are highly toxic or amphotericin B 
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treatment that is highly expensive17. Thus, new drug development strategies are required 
for combating this lethal disease. 
The cell wall and extracellular matrix of Leishmania major is composed of 
glycoconjugates such as glycophosphatidylinositol (GPI), lipophosphoglycan (LPG) and 
glycoinositolphospholipids (GIPLs) that consist of galactofuranosyl residues (Fig. 1.2b). 
Gene deletion studies in L. major have shown that mice infected with Δglf mutant 
delayed the appearance of lesions at the site of infection by ~3-4 weeks (Fig. 1.4) thus, 
attenuating the virulence5a. 
 
      
 
      Fig. 1.4 Virulence of the glf- mutant is attenuated in a murine infection model5a. 
 
 
1.2.3 Role of galactofuranose in the pathogenesis of Trypanosoma cruzi 
 
 Chagas disease or American trypanosomiasis is a vector-borne disease, 
transmitted to humans by triatomine bug. The disease can be transmitted by blood 
transfusion, organ transplantation, congenital transmission and by ingesting contaminated 
food and drinks. Chagas disease was initially thought to be affecting only people living in 
 7 
endemic areas of Latin America, but recent reports have suggested that more than 
300,000 people living in United States are infected with this disease18.   
 In T. cruzi, Galf is present in glycoinositolphospholipids (GIPLs), N- and O-
linked glycans and GPI-linked glycoproteins of the cell surface structures1a. As UGM is a 
central enzyme involved in Galf metabolism, targeting this enzyme would provide a 
novel strategy for developing inhibitors against this disease.  
 
1.3 Structural characterization of prokaryotic UGMs 
 
The first structure of UGM was determined from Escherichia coli in 20013. Since 
then, several structures of UGMs from Mycobacterium tuberculosis4a, Klebsiella 
pneumoniae and Dienococcus radiodurans19 have been determined with and without 
substrate; but no eukaryotic UGM structure was determined until this work. Although the 
residues in flavin-binding domain and substrate-binding site are mostly conserved, 
bacterial UGMs share only ~15% global sequence identity with eukaryotic UGMs.  
 Even after the determination of structures of prokaryotic UGMs, several questions 
about UGMs are still unanswered. UGMs are active in their reduced state but so far, not 
much is known about the biological reducing partners of the enzyme3, 20. Moreover, 
structures of bacterial UGMs show no variation in the hydrogen-bonding pattern in the 
oxidized and reduced states. Both the states have a hydrogen bond formed between N5 of 
FAD isoalloxazine and backbone carbonyl of Gly residue4a. However, this pattern is 
characteristic of the reduced state of enzyme. Thus, structural characterization of 
eukaryotic UGMs might help us in determining the structural changes associated with 
different redox states of FAD and understand the enzymatic mechanism.  
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1.4 Proposed enzymatic mechanism for UGM 
 
UGM is an atypical flavoenzyme that catalyzes the reversible reaction between 
UDP-Galp and UDP-Galf without any net redox change3. Positional isotope exchange 
experiments have shown that the reaction proceeds with the cleavage of the bond 
between the anomeric carbon C1 and UDP moiety21. 
Earlier evidences suggested that the reaction occurs by one-electron transfer 
forming an oxocarbenium intermediate22 . Recently, a novel role for flavin was proposed 
where N5 of the FAD isoalloxazine acts as a nucleophile and attacks the anomeric carbon 
C1 of the galactose moiety to form a covalent flavin-iminium adduct (Fig. 1.5)23. The 
UDP moiety is then displaced from UDP-Galp or UDP-Galf via SN2- type mechanism24. 
 
 
 
Fig. 1.5 Mechanism involving flavin-iminium adduct as the intermediate in the reaction catalyzed by 
UGM25. 
 
1.6 Conclusion 
 
 UGM plays a central role in the virulence of pathogenic fungi and protozoa such 
as Aspergillus fumigatus, Trypanosoma cruzi and Leishmania major. These pathogenic 
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protozoa are implicated in neglected tropical diseases that have gained tremendous 
attention worldwide because of high mortality rates16, 18. Due to emigration and 
globalization, these diseases that were once endemic to tropical and mediterranean 
regions, have now also emerged in parts of United States and Europe14, 18.  
 In addition to its medical relevance, UGM has a unique chemistry among 
flavoenzymes that has never been observed before. Thus, the determination of three-
dimensional structures of eukaryotic UGMs might help us in elucidating the enzymatic 
mechanism of this class of enzymes and potential inhibitor design. 
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Abstract 
 UDP-galactopyranose mutase (UGM) is a flavoenzyme that catalyzes the 
conversion of UDP-galactopyranose to UDP-galactofuranose, which is a central reaction 
in galactofuranose biosynthesis. Galactofuranose has never been found in humans but is 
an essential building block of the cell wall and extracellular matrix of many bacteria, 
fungi, and protozoa. The importance of UGM for the viability of many pathogens and its 
absence in humans make UGM a potential drug target. Here we report the first crystal 
structures and small-angle x-ray scattering data for UGM from the fungus Aspergillus 
fumigatus, the causative agent of aspergillosis. The structures reveal that Aspergillus 
UGM has several extra secondary and tertiary structural elements that are not found in 
bacterial UGMs yet are important for substrate recognition and oligomerization. Small 
angle x-ray scattering data show that Aspergillus UGM forms a tetramer in solution, 
which is unprecedented for UGMs. The binding of UDP or the substrate induces 
profound conformational changes in the enzyme. Two loops on opposite sides of the 
active site move toward each other by over 10 Å to cover the substrate and create a 
closed active site. The degree of substrate-induced conformational change exceeds that of 
bacterial UGMs and is a direct consequence of the unique quaternary structure of 
Aspergillus UGM. Galactopyranose binds at the re face of the FAD isoalloxazine with 
the anomeric carbon atom poised for nucleophilic attack by the FAD N5 atom. The 
structural data provide new insight into substrate recognition and the catalytic mechanism 
and thus will aid inhibitor design. 
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2.1 Introduction 
 
 UDP-galactopyranose mutase (UGM) is a unique flavoenzyme that catalyzes the 
reversible conversion of UDP-galactopyranose (UDP-Galp) to UDP-galactofuranose 
(UDP-Galf) (Fig. 2.1). Unlike flavin-dependent oxidoreductases, the redox state of the 
flavin in UGM is unchanged upon product formation1. Although it is known that the FAD 
must be reduced for maximal catalytic activity, the precise role that the flavin plays in 
catalysis remains controversial. 
    
    Fig. 2.1 Reaction catalyzed by UGM. 
 
 UGM is also an attractive target for drug design. The carbohydrate moiety of the 
product of the reaction, galactofuranose (Galf), is the five-membered ring form of the 
common monosaccharide galactose. Galf has never been found in mammals and higher 
plants but is an essential building block of the cell wall and extracellular matrix of many 
bacteria, fungi, and protozoa2. The UGM reaction is central to Galf biosynthesis. Gene 
deletion studies have shown that UGM is essential for mycobacterial growth3 and 
contributes to the virulence of the pathogenic fungus Aspergillus fumigatus4 and the 
protozoan parasite Leishmania major5. In summary, the importance of UGM for the 
viability of many pathogens and its absence in humans make UGM a potential drug 
target.  
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 This study focuses on the UGM from A. fumigatus. Aspergillus spp. are 
ubiquitous fungi that cause diseases ranging from allergic reactions and lung infections to 
sepsis and death6. Acquired by inhalation of airborne spores, Aspergillus infections 
(mainly A. fumigatus) can lead to invasive pulmonary aspergillosis, particularly in 
immunocompromised persons(6,7,8). Invasive pulmonary aspergillosis is also an emerging 
serious infection in patients with chronic obstructive pulmonary disease9. The overall 
case fatality rate associated with invasive aspergillosis is 58%10. Also, bronchial 
colonization by A. fumigatus in people with asthma or cystic fibrosis causes allergic 
bronchopulmonary aspergillosis, a hypersensitivity lung disease that can lead to airway 
destruction and widening and scarring of the lung, resulting in significant morbidity and 
mortality11. The ubiquity of the fungus, the increasing occurrence of Aspergillus 
infections in humans, and the high mortality rate associated with invasive pulmonary 
aspergillosis demonstrate the need for new anti-Aspergillus drugs.  
 Inhibition of A. fumigatus UGM (AfUGM) is a potential strategy for the 
development of new drugs to treat patients with aspergillosis. In Aspergillus, Galf is 
present in the galactomannan fraction of the cell wall, N - and O-glycans of secreted 
glycoproteins, glycosylphosphatidylinositol-anchored lipophosphogalactomannan, and 
sphingolipids12. It is estimated that Galf constitutes 5% of the dry weight of A. 
fumigatus12. Deletion of the UGM gene in A. fumigatus results in a thinner cell wall and 
increased susceptibility to drugs4. Furthermore, the mutated strain exhibits attenuated 
virulence in a low-dose mouse model of invasive aspergillosis4. In another study, deletion 
of the UGM gene resulted in a reduced growth phenotype, but virulence as measured in a 
higher dose mouse model was unimpaired13. The different outcomes of the two deletion 
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studies may reflect the different doses used, with the low-dose model generally 
considered to mimic more closely the in vivo situation2. Because of the importance of 
UGM for the fitness of A. fumigatus, UGM is a promising target for the development of 
new drugs for adjunctive treatment for aspergillosis (2,4). 
 Here we report four crystal structures of AfUGM along with an analysis of the 
oligomeric state and quaternary structure in solution using small-angle x-ray scattering 
(SAXS). The data reveal interesting differences from bacterial UGMs, including 
additional secondary structure elements, unique mode of oligomerization, and profound 
conformational changes induced by substrate binding. The structures should aid inhibitor 
design efforts. 
 
2.2 Materials and Methods  
2.2.1 Crystallization 
 
 Crystallization screens of AfUGM and Se-Met AfUGM were performed at 21°C 
and 4°C using the sitting-drop and hanging drop methods of vapor diffusion, as well as 
microbatch. These screens were performed using ligand-free protein and protein that had 
been incubated with UDP-glucose, UMP, or UDP. Initial structure determination efforts 
were hampered by translational pseudosymmetry (TPS). Crystal screening and 
optimization yielded two crystal forms that exhibit TPS. One of these forms appeared as 
hexagonal blocks in ammonium sulfate and diffracted to 3.4 Å resolution. The optimal 
reservoir contained 1.6 M ammonium sulfate, 5 % PEG 400, and HEPES buffer at pH 7.5 
The apparent Laue symmetry is 6/mmm with unit cell lengths of a = 202 Å, c = 355 Å. 
The native Patterson map calculated using phenix.xtriage 15 exhibited a peak at (u = 0, v = 
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0, w = 0.49) with a height of 48 % relative to the origin peak, which suggests strong TPS. 
This crystal form was also obtained under low ionic strength conditions, such as 13% 
polyethylene glycol (PEG) 8000 and HEPES buffer at pH 8.0. Curiously, the external 
morphology of the PEG form was thin blades instead of hexagonal blocks. Nevertheless, 
the lattice and TPS were identical to that of the ammonium sulfate form. Various PEG 
solutions also yielded an orthorhombic crystal form, which diffracted to 3.2 Å. The 
apparent Laue symmetry is mmm with a = 111 Å, b = 207 Å, and c = 234 Å. The native 
Patterson map exhibited a strong (22 - 45 %) off-origin peak near (0, 0.25, 0.5), 
indicating TPS. Se-Met SAD phasing was attempted with these crystal forms, but the 
maps were not interpretable. Additive screening was used to identify new crystal forms. 
The most promising result was obtained using ammonium sulfate as the precipitant and 
isopropanol as the additive. The inclusion of 5 % isopropanol changed the morphology 
from hexagonal block to hexagonal bipyramid. The apparent Laue symmetry is 6/mmm 
with cell dimensions of a = 217 Å, c = 325 Å. Note that these dimensions are about 8 % 
different from those obtained in the absence of isopropanol. Moreover, the native 
Patterson map did not indicate TPS. However, these crystals diffracted to only about 
5.5Å resolution. Structure determination via Se-Met SAD phasing failed, due presumably 
to poor data quality. Several site-directed mutants of AfUGM were screened to identify 
crystal forms that are free of pathologies and diffract to higher resolution. The mutations 
were designed from a homology model of AfUGM calculated using Phyre 16. The mutant 
enzymes that were subjected to crystal screening included the predicted active site 
mutants W167A, R211A, R327K, and W204A, as well the predicted surface double 
mutants K231A/K233A, K239A/K241A, K344A/K345A, and K363A/E364A. Most of 
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the aforementioned undesirable crystal forms were also observed with the mutant 
enzymes. This difficulty was circumvented by using the double mutant enzyme 
K344A/K345A for structure determination. The kinetic constants of K344A/K345A are 
virtually identical to those of the native enzyme (Table 2.1), and the structures show that 
residues 344 and 345 are on the surface of the enzyme, far from the active site and 
oligomerization interfaces.  
 
Table 2.1 Steady state kinetics of AfUGM and K344A/K345A. 
 kcat Km kcat/Km 
Native 60 ± 3 70 ± 10 0.84 ± 0.13 
K344A/K345A 55 ± 2 70 ± 9 0.75 ± 0.07 
 
 AfUGM mutant K344A/K345A (referred to hereafter as AfUGM) was expressed 
and purified as described for the native enzyme14. Se-Met AfUGM was produced using 
the metabolic inhibition method15. Crystals were grown in sitting drops at room 
temperature using drops formed by mixing 1.5 μl of the protein stock solution with an 
equal volume of the reservoir. The protein stock solution consisted of 8 mg/ml protein in 
25 mM HEPES, 125 mM NaCl, 5 mM L-cysteine, and 0.5 mM 
Tris(hydroxypropyl)phosphine at pH 7.5. The optimal reservoir contained 1.5 M 
ammonium sulfate and 0.1 M sodium acetate, pH 4.5. The crystals appeared as large, 
yellow hexagonal bipyramids. The crystals were cryoprotected by exchanging the mother 
liquor with 1.8 M ammonium sulfate, 0.1 M sodium acetate, pH 4.5, and 25% glycerol. 
The space group is P6522 with unit cell dimensions of a = 218 Å and c = 320 Å. Although 
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a conventional estimate of the solvent content using the method of Matthews16 yields the 
expectation of eight molecules in the asymmetric unit, there are, in fact, only four 
molecules present. The solvent content and VM are thus 75% and 4.9 Å3/Da. 
 
2.2.2 Crystal Soaking 
 
 Crystals of reduced AfUGM with and without bound active site ligands were 
prepared by soaking the aforementioned crystals. Crystals of ligand-free reduced AfUGM 
were prepared by soaking crystals in the cryobuffer supplemented with 80 mM dithionite. 
At this concentration, the enzyme is fully reduced in solution14. Indeed, the yellow color 
of the crystals was bleached upon soaking, indicating that the FAD is reduced. When the 
transformation was complete (2–3 min), the crystals were plunged into liquid nitrogen to 
trap the reduced state. Crystals of the reduced enzyme complexed with UDP were 
prepared by soaking with the cryobuffer supplemented with 80 mM dithionite and 40 
mM UDP. The soaking time was ∼30 min. Crystals of the reduced enzyme complexed 
with UDP-Galp were prepared similarly using 80 mM dithionite and 100 mM UDP-Galp. 
As with the ligand-free enzyme, the crystals of the ligand complexes were colorless when 
frozen. 
 
2.2.3 X-ray Diffraction Data Collection, Phasing, and Refinement 
 
 Crystals were analyzed at beamlines 19ID and 24-ID-C of the Advanced Photon 
Source and beamline 8.2.2 of the Advanced Light Source. The 19ID data sets were 
processed with HKL3000 17. The other data sets were integrated with XDS and scaled 
with SCALA18 via CCP4i19. 
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 The first structure of AfUGM was determined using single-wavelength 
anomalous diffraction phasing based on data collected at 19ID from Se-Met AfUGM 
crystals (Table 2.2). Several single-wavelength anomalous diffraction data sets were 
collected at the wavelength corresponding to the experimentally measured peak of f″. The 
phasing potential of each data set was assessed with the HKL2MAP interface20 to the 
SHELXC/D/E programs (21,22). A 2.65 Å resolution data set with good anomalous signal 
was identified, from which a 56-atom selenium constellation was deduced. This 
constellation was input to PHENIX AutoSol23 for single-wavelength anomalous 
diffraction phasing, density modification, and automated building. After density 
modification, the figure of merit improved from 0.42 to 0.77 for all reflections to 2.65 Å 
resolution. The model from automated building consisted of 1956 residues, 1778 of 
which were assigned to sequence. This model was adjusted and extended manually in 
COOT 24, aided by the density-modified single-wavelength anomalous diffraction map, 
and subsequently refined against a 2.35 Å resolution native data set using PHENIX25. 
Several additional rounds of building and refinement were performed. The resulting 
structure provided the starting coordinates for the refinements of the other structures 
reported here. Data collection and refinement statistics and Protein Data Bank (PDB) 
deposition codes are listed in Table 2.2. 
 
2.2.4 Small angle X-ray Scattering 
 
 SAXS experiments were performed at the SIBYLS beamline (12.3.1) of the 
Advanced Light Source26. Prior to analysis, a sample of AfUGM at 9.4 mg/ml was 
dialyzed into a buffer of 20 mM HEPES, 45 mM NaCl, 0.5 mM 
Tris(hydroxypropyl)phosphine at pH 7.5. Scattering intensities (I) were measured at three 
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nominal protein concentrations to ensure concentration-independent scattering. 
Exposures of 0.5, 1.0, and 5.0 s were used to check for radiation damage. The scattering 
curves collected from the protein sample were corrected for background scattering using 
intensity data collected from the dialysis buffer. A composite scattering curve was 
generated with PRIMUS27 by scaling and merging the background corrected high q 
region data from the 5.0-s exposure with the low q region data from the 0.5-s exposure. 
The pair distribution function was calculated with GNOM 28. GASBOR 29 was used to 
calculate shape reconstructions, and DAMAVER 30 was used to average and filter the 
resulting dummy atom models. The Situs module pdb2vol was used to convert the 
averaged, filtered models into volumetric maps 31. SUPCOMB was used to superimpose 
the crystallographic tetramer onto the dummy atom model 32. 
 
2.2.4 Kinetics 
 
 The mutase activity was tested with UDP-Galf as the substrate following 
procedures previously described 14. The enzyme concentration was determined using the 
flavin extinction coefficient at 450 nm of 10.6 mM−1cm−1 14. 
 
2.2.5 Structure Analysis 
 
 SSM 33 was used for structure superposition. The PDBePISA server was used to 
analyze protein interfaces in crystal lattices 34. COOT and PyMOL 35 were used to 
analyze noncovalent interactions. 
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Table 2.2 X-ray Diffraction Data Collection and Refinement statistics. 
 
 Se-Met Sulfate 
complex 
AfUGMr AfUGMr-UDP AfUGMr-
UDP-Galp 
Beamline APS 19ID APS 19ID ALS 8.2.2 ALS 8.2.2 APS 24-ID-C 
Active site ligand Sulfate sulfate None UDP UDP-Galp 
Space group P6522 P6522 P6522 P6522 P6522 
Unit cell parameters 
(Å) 
a= 218.1, 
c= 319.1 
a=217.8,         
c=319.7 
a= 217.9, 
c= 322.8 
a= 218.2, 
c= 320.8 
a= 219.1, 
c= 322.4 
Wavelength 0.97915 0.97915 1.00000 1.00000 0.97949 
Resolution (Å) 55.00-2.65  
(2.74-2.65) 
50.0-2.35    
(2.43-2.35) 
48.6-2.20 
(2.37-2.25) 
48.6-2.25 
(2.37-2.25) 
48.8-2.25 
(2.37-2.25) 
Observations 1,833,668 900,659 1,560,709 1,036,765 1,670,151 
Unique reflections 128,441 167,455 211,192 205,755 207,614 
Rmerge(I) 0.087 (0.351) 0.086 (0.568) 0.097 (0.599) 0.086 (0.676) 0.097 (0.599) 
Rmeas(I)   0.104 (0.643) 0.096 (0.753) 0.104 (0.645) 
Rpim(I)   0.038 (0.231) 0.041 (0.323) 0.035 (0.232) 
Mean I/σ 32.3 (5.5) 20.1 (3.0) 16.2 (3.5) 17.6 (2.8) 13.9 (3.4) 
Completeness (%) 99.0 (99.6) 90.5 (91.1) 99.8 (100.0) 97.9 (99.7) 97.3 (97.6) 
Multiplicity 14.3 (12.7) 5.4 (5.4) 7.4 (7.4) 5.0 (5.0) 8.0 (7.0) 
No. of protein chains  4 4 4 4 
No. of protein 
residues 
 2018 2020 2019 2019 
No. of protein atoms  15597 15580 15551 15562 
No. of FAD atoms  212 212 212 212 
No. of ligand atoms  0 0 50 72 
No. of water 
molecules 
 516 813 657 659 
Rcryst   0.188 (0.249) 0.190 (0.244) 0.192 (0.260) 0.185 (0.249) 
Rfreeb  0.218 (0.297) 0.215 (0.281) 0.218 (0.297) 0.210 (0.294) 
rmsd bond lengths, Åc  0.007 0.007 0.007 0.007 
rmsd bond angles, °  1.06 1.04 1.07 1.08 
Ramachandran plotd      
  Favored (no. 
residues) 
 1985 1983 1979 1977 
  Allowed (no. 
residues) 
 25 29 32 34 
  Outliers (no. 
residues) 
 0 0 0 0 
Average B-factor 
(Å2) 
     
  Protein  35 30 33 35 
  FAD  32 25 30 31 
  Active site ligand  56  26 39 
  Water  34 34 34 37 
Coordinate error (Å)e  0.33 0.32 0.32 0.32 
PDB code  3UTE 3UTF 3UTG 3UTH 
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aValues for the outer resolution shell of data are given in parenthesis.  
bA common set of test reflections (5 %) was used for refinement of all structures. 
cCompared to the parameters of Engh and Huber46. 
eThe Ramachandran plot was generated with RAMPAGE47. 
fMaximum likelihood-based coordinate error estimate. 
 
2.3 Results 
2.3.1 Overall Fold and Flavin Binding Site 
 
 The AfUGM protomer has a mixed α/β-fold (Fig. 2.2) and exhibits the same three 
domain architecture that was first identified in the structure of Escherichia coli UGM 36. 
Domain 1 is the largest of the three domains. It is a tripartite unit consisting of residues 
3–90, 205–291, and 421–507 and includes a Rossmann fold core that binds the FAD. 
Domain 2 is a bundle of α-helices (residues 105– 204). This domain mediates one of the 
major interfaces of the tetramer. Domain 3 (residues 91–104, 292–420) is situated 
between the other two domains and features a twisted, seven-stranded β-sheet. This 
domain participates in substrate binding. The FAD isoalloxazine binds in a crevice 
between domains 1 and 3.  
 AfUGM is about 100 residues longer than bacterial UGMs, and the extra residues 
form several structural elements that appear to be important for catalysis and 
oligomerization (Fig. 2.2A, red sections). The first of these extra elements is a 
fourstranded β-sheet in domain 1 formed by residues 6–8 and 243–262. This β-sheet is 
located near the adenine of the FAD. Domain 2 has an extra helix (residues 188–197) not 
found in bacterial UGMs. This helix is situated between two mobile flaps that close and 
open in response to substrate binding and product release, respectively (Fig. 2.2A). Also, 
the second helix of the domain (residues 115–134) is about seven residues longer in 
AfUGM and rotated by about 90° from the corresponding helix in bacterial UGMs. The 
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115–134 and 188–197 helices form a four-helix bundle in one of the dimer interfaces of 
the UGM tetramer (see below). 
 
   
Fig. 2.2 Overall fold of AfUGM.  (A) Structure of the AfUGM protomer.  Domains 1, 2, and 3 are colored 
blue, yellow, and green, respectively.  Features that distinguish AfUGM from bacterial UGMs are colored 
red. (B) Protomer structure of a bacterial UGM (Deinococcus radiodurans UGM, PDB code 3HE3).   This 
figure and others were prepared with PyMol.  
 
Domain 3 of AfUGM has two large inserts when compared with bacterial UGMs. 
The first is a long loop formed by residues 335–366. The second consists of residues 
378–418, which fold into an α-helix followed by a β-strand. Because of the latter 
secondary structure element, the sheet of domain 3 has seven strands rather than six as in 
bacterial UGMs. Finally, AfUGM has ∼30 extra residues at the C terminus. These 
residues form a U-shaped substructure that packs against domain 1 and features two α-
helices. This extra structural element is involved in oligomerization. 
 
2.3.2 Quaternary Structure 
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 SAXS was used to obtain solution structural information for AfUGM. A 
composite scattering curve is shown in Fig. 2.3A. The associated Guinier plot exhibits 
good linearity (R2 = 0.9996) and suggests a radius of gyration of 47.3 Å (Fig. 2.3A, 
inset). Calculations of the pair distribution function yield a Rg of 47.6 Å and maximum 
particle dimension of 140 Å (Fig. 2.3B). For reference, the Rg of the crystallographic 
protomer is only 24 Å. These results suggest that AfUGM self-associates in solution.  
 The SAXS data were further analyzed to determine the oligomeric state and 
quaternary structure. The experimental scattering profile was compared with theoretical 
profiles calculated from models of AfUGM oligomers. These models were obtained by 
analyzing the protein interfaces in the crystal lattice to identify potentially stable 
assemblies. The calculations revealed an octamer with Rg of 52 Å, a tetramer exhibiting 
point group 222 symmetry and having an Rg of 47 Å, and two symmetric dimers with Rg 
values of 34 Å (OP dimer) and 43 Å (OQ dimer). The Rg data suggest that AfUGM forms 
a tetramer. Indeed, only the profile calculated from the tetramer shows good agreement 
with the experimental curve (Fig. 2.3C). 
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Fig. 2.3 SAXS analysis. (A) SAXS curve and Guinier plot (inset). The range of the Guinier plot 
corresponds to qRg = 0.503 - 1.31.  (B) Pair distribution function.  (C) Comparison of the experimental 
SAXS curve (black) with theoretical curves calculated from various oligomeric models of AfUGM.  The 
inset highlights the fits in the low q region (q < 0.1 Å-1).  
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Note in particular that the agreement is exceptional for the low q region (q < 0.1, 
Fig. 2.3C, inset). These results are consistent with size exclusion chromatography data, 
which suggested that AfUGM forms a tetramer in solution14. Finally, shape 
reconstruction calculations performed with GASBOR assuming a 222 tetramer yield an 
envelope that is in good agreement with the crystallographic tetramer (Fig. 2.4). It is 
concluded that the tetramer identified in the crystal lattice represents the solution 
structure of AfUGM. The AfUGM tetramer is a dimer of dimers with point group 222 
symmetry (Fig. 2.4). The symmetry of the tetramer can be described with three mutually 
orthogonal 2- fold axes, denoted P, Q, and R that intersect at the center of the tetramer. 
The P-, Q-, and R-axes relate protomer O to protomers P, Q, and R, respectively. The 
axes define three potential dimer interfaces corresponding to protomer O contacting the 
other three protomers. Only the OP and OQ interfaces are significant.  
 The OP interface buries 5000 Å2 of area and is primarily hydrophilic, featuring 10 
intersubunit hydrogen bonds. The interface is noncontiguous. The major part of the 
interface consists of the C-terminal residues 468–502 of two P-related chains interacting 
across the P-axis at the distal ends of the tetramer. Two such interfaces are located at 
opposite ends of the tetramer (Fig. 2.4). The minor part of the OP interface is located at 
the intersection of the two-fold axes and involves just the guanidinium of Arg-133 
forming a hydrogen bond with the carbonyl of Val-134 of the P-related chain (Fig. 2.4A, 
boxed inset). Thus, there are four of these intersubunit hydrogen bonds located in the 
center of the tetramer. 
 The OQ interface is located in the middle of the tetramer and buries 4600 Å2 of 
contiguous surface area. Two helices (residues 115–134 and 188–197) from domain 2 of 
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Q-related chains interact to form a four-helix bundle oriented parallel to the Q-axis (Fig. 
2.4). Note that these two helices are unique to AfUGM (Fig. 2.4 A). The tetramer has two 
of these bundles. The four-helix bundle has a hydrophobic interior featuring Val, Leu, 
and Ile side chains. 
 
   
Fig. 2.4 Quaternary structure of AfUGM. (A) The tetramer is viewed down the R molecular 2-fold axis.  
Each chain has a different color.  The active site flaps of chain Q are colored red. The surface represents the 
SAXS shape reconstruction.  Inset: Intersubunit hydrogen bonds at the intersection of molecular 2-fold 
axes.  Chains related by the P-axis engage in hydrogen bonding.  The oval represents the R two-fold 
molecular axis. (B) The tetramer is viewed down the Q-axis. 
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2.3.3 Active Site of Sulfate Complex 
 
 
 The crystals used for structure determination were grown in 1.5 M ammonium 
sulfate, and as crystallized, two sulfate ions are bound in the active site (Fig. 2.5). The 
ions bind on the re side of the isoalloxazine. One of the ions binds next to the center ring 
of the isoalloxazine, which is the binding site for the Galp moiety of the substrate. His-
63, an absolutely conserved residue in UGMs, is likewise located on the re face and 
interacts with both sulfate ions. The location of the conserved histidine at the re face is 
unprecedented and likely a crystallization artifact.  
 The isoalloxazine is planar, which is consistent with the FAD being oxidized. It is 
noted that the crystals are yellow, which is also indicative of the oxidized state. 
 
      
 
 
Fig. 2.5 Stereographic views of histidine loop in the (A) sulfate complex and (B) AfUGMr. In both panels, 
the cage represents a simulated annealing σA-weighted Fo - Fc omit map contoured at 3.0 σ. 
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2.3.4 Histidine Loop of Reduced AfUGM 
 
 
 The structure of the reduced enzyme (AfUGMr) was determined from a crystal 
that was soaked in 80 mM sodium dithionite. The crystal changed from yellow to 
colorless, which indicated that the FAD was reduced. 
 Soaking with dithionite causes significant changes in the active site, which occur 
in all four chains. Electron density features for the sulfate ions are absent, and the 
conformation of the histidine loop is dramatically different (Fig. 2.5B). In particular, His-
63 has moved to the si face of the FAD, where it stacks in parallel with the middle ring of 
the isoalloxazine and forms a hydrogen bond with the FAD 2′-OH. Furthermore, the 
carbonyl of Gly-62 forms a hydrogen bond with the FAD N5. This conformational 
change in the protein is accompanied by a 3 Å shift in the FMN part of the FAD. This 
shift brings the N1 atom of the FAD within hydrogen-bonding distance of the backbone 
N-H group of Gln-458, which is consistent with the FAD adopting the anionic 
hydroquinone state.  
 The conformation of the histidine loop in AfUGMr is very similar to those of 
bacterial UGMs. In particular, in all other structures, the conserved histidine is located at 
the si face as in AfUGMr. Furthermore, in all other UGMs, the carbonyl of the residue 
preceding the conserved His accepts a hydrogen bond from the N5 of reduced FAD. The 
carbonyl-N5 interaction is important for stabilizing the reduced state of FAD, a necessity 
for activity. As mentioned, Gly-62 forms this critical hydrogen bond in AfUGMr. It is 
concluded that the dithionite-reduced AfUGM structure represents the active, substrate-
free form of the enzyme.  
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2.3.5 FAD Conformation and Binding Site 
 
 
 The FAD of AfUGMr binds primarily to domain 1 (Fig. 2.2A). The conformation 
of the FAD is nearly identical to those of bacterial UGMs, and the flavin-protein 
interactions are highly conserved (Fig. 2.6). In particular, there are several interactions 
with the protein backbone (Fig. 2.6B); these are conserved, as one would expect. Asp-38 
forms two hydrogen bonds with the ribose. This interaction appears to be universal in 
UGM. Some of the side chain interactions with the FAD in AfUGM are found in other 
bacterial UGMs. For example, Ser-461 and Thr-18, which interact with the ribityl 3′-OH 
and pyrophosphate, respectively, are analogous to Thr-355 and Ser-14 of Klebsiella 
pneumoniae UGM (KpUGM). 
 The FAD of AfUGMr exhibits a butterfly-like distortion of the isoalloxazine in 
which the pyrimidine ring bends 7° out of the plane such that the si face is concave (Fig. 
2.6C). The direction of the bending is the same as that of Deinococcus radiodurans UGM 
(DrUGM) 37and opposite to that of KpUGM38. The angle is close to that of DrUGM and 
about half that of KpUGM (∼13°). 
 
 
 34 
    
 
 
Fig. 2.6 Electron density and interactions for the FAD in AfUGMr. (A) View of the FAD oriented with the 
re side of the isoalloxazine system facing the viewer. The cage represents a simulated annealing σA 
weighted Fo - Fc omit map contoured at 3.0 σ. (B) Schematic diagram of protein-FAD interactions in 
AfUGMr. Backbone interactions are indicated by N or O in parentheses. (C) Edge-on view of the 
isoalloxazine. The horizontal line assists in seeing the 7° butterfly-like bend angle. 
 
 
2.3.6 Structure of AfUGMr Complexed with UDP 
 
 The structure of AfUGMr complexed with UDP was determined from a crystal 
that had been soaked in sodium dithionite and UDP. Electron density maps clearly 
indicated that UDP is bound in two of the four active sites of the tetramer (Fig. 2.7). The 
occupancy of UDP is estimated to be 0.9, which indicates essentially full occupancy and 
thus tight binding. 
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Fig. 2.7 Electron density maps UDP bound to AfUGMr (stereographic view). The cage represent a 
simulated annealing σA-weighted Fo - Fc omit maps contoured at 3.0 σ.  
 
 
 The binding of UDP induces profound conformational changes in the enzyme 
(Fig. 2.8). The largest of these changes involves residues 179–187 and 203–209. In the 
absence of UDP, these loops reside on the periphery of the enzyme, and thus, the active 
site is open. Upon binding, the loops move toward each other like the flaps of a box top 
to create a closed active site. The conformational changes are substantial. For example, 
the middle residues of the two loops, Val-183 and Pro- 206, move by 11 and 13 Å, 
respectively, upon ligand binding. One consequence of the flaps folding inward is that the 
side chain of Phe-66 swings into the active site to avoid a clash with Pro-206 (Fig. 2.8). 
As shown below, Phe-66 contacts the Galp moiety of the substrate.  
 Closing of the flaps is accompanied by smaller conformational changes in 
residues 104–107 and 146–161 that fine-tune the uridine binding pocket. Tyr- 104 and 
Phe-158 move apart from each other by 3 Å to create space for the incoming uracil. Phe-
106 and Gln-107 shift by 1.0 and 2.0 Å, respectively, to form three hydrogen bonds with 
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the base (interactions are shown in Fig. 2.7). Finally, movements of ∼1.0 Å bring Asn-
163, Trp-167, Tyr-317, Arg-327, and Tyr-453 into contact distance of the ribose and 
pyrophosphate (Fig. 2.7).  
  
  
Fig. 2.8 Comparison of the open and closed forms of AfUGMr (stereographic view). AfUGMr is shown in 
yellow.  The AfUGMr-UDP complex structure is shown in green. UDP is colored pink.  Selected 
interactions in the closed state are indicated by dashed lines.   
 
 The dramatic closing of the flaps also results in the formation of new protein-
protein interactions that stabilize the closed active site conformation (Fig. 2.8). In 
particular, Glu-181 and Arg-182 of the 180s flap interact with His-68 and Asn- 457, 
respectively, in the closed state, whereas in the open state, the interacting partners are 
separated by 17–19 Å. Another interaction that stabilizes the closed state involves Arg-
91, whose side chain moves to make four hydrogen bonds with the 200s flap. 
 
2.3.7 Structure of AfUGMr Complexed with UDP-Galp 
 
 
 The structure of AfUGMr complexed with the substrate UDP-Galp was 
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determined from a crystal that was soaked in sodium dithionite and UDP-Galp. As with 
the UDP complex, electron density maps indicated binding in two of the four active sites 
(Fig. 2.8A). The occupancy of UDP-Galp is estimated to be 0.8. Electron density is weak 
for the O5 atom of the Galp moiety, suggesting the possibility of conformational disorder 
in this part of the ring. We note that conformational disorder of the Galp moiety has been 
observed previously38 (PDB code 3INT). As seen with UDP, the substrate induces closure 
of both flaps.  
 The conformation and interactions of the UDP moiety of the substrate are 
essentially identical to those of the AfUGMr-UDP complex, so we will focus on the Galp 
moiety. Galp binds at the re face of the FAD isoalloxazine with the anomeric carbon 
atom (C1) poised 3.4 Å from the FAD N5 atom (Fig. 2.9A, red dashes). The hydroxyl 
groups of Galp make direct hydrogen bonds with Arg-182, Asn-207, and Asn-457 (Fig. 
2.9B). Water-mediated interactions are formed with Thr-329, Tyr-334, and Arg-447. 
Also, the O4 hydroxyl forms a hydrogen bond with the FAD O4 carbonyl. In addition to 
these electrostatic interactions, nonpolar contacts are formed with Phe-66 and Trp-315. 
These steric interactions presumably help enforce specificity for Galp and orient the 
carbohydrate for catalysis.  
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Fig. 2.9 Electron density map (stereographic view) and interaction diagram for UDP-Galp bound to 
AfUGMr. (A) The cage represent a simulated annealing σA-weighted Fo - Fc omit map contoured at 2.0 σ.  
The red dashes in panel indicate the 3.4 Å separation between the anomeric C atom of Galp and the FAD 
N5. (B) Schematic diagram of noncovalent electrostatic interactions.   
 
2.3.8 Comparison of UDP-Galp Interactions in AfUGM and Bacterial 
UGMs 
 
 The structures of the UDP-Galp complexes of AfUGM, KpUGM, and DrUGM 
were compared to identify similarities and differences in substrate recognition (Fig. 2.10). 
In all three structures, the substrate adopts an extended conformation, the O4 hydroxyl of 
Galp forms a hydrogen bond to the FAD O4, and the anomeric carbon atom is near the 
FAD N5. Several conserved residues participate in substrate recognition, including Arg-
182, Arg-327, Trp-167, Tyr- 419, and Tyr-453 (AfUGM numbering).  
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Fig. 2.10 UDP-Galp recognition by eukaryotic and bacterial UGMs (stereographic view). The structuresof 
AfUGM (white), KpUGM (cyan, 3INT), and DrUGM (yellow, 3HDY) complexed with UDP-Galp are 
shown. Selected residues of AfUGM are noted. 
 
 
 Differences between the two classes of UGM are also evident (Fig. 2.10). In 
particular, the UMP moiety of AfUGM is displaced by 3–5 Å when compared with the 
bacterial enzymes. The uracil ring is shifted by ∼4 Å and rotated by almost 90°. This 
difference allows the uracil to form two hydrogen bonds with Gln-107, a residue without 
a counterpart in bacterial UGMs. Displacement of the UMP also reflects a different 
arrangement of Tyr residues that interact with the pyrophosphate (Tyr-317 in AfUGM, 
Tyr-185 in KpUGM, Tyr-209 in DrUGM). Finally, the O6 hydroxyl of Galp in AfUGM 
is rotated by 110° from that in the bacterial enzymes. This difference is due to the 
potential for steric clash with Trp-315. 
 
2.4 Discussion 
 The core structure of UGM appears to be conserved across the bacterial and 
eukaryotic domains of life despite low sequence identity (∼16%). The root mean square 
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deviation between AfUGM and bacterial UGMs is 2.4–2.7 Å over 279–322 residues. 
Also, the majority of the FAD-protein interactions are conserved.  
 Curiously, protoporphyrinogen oxidase from Myxococcus xanthus (PPOX) 39, 
rather than another UGM, is the closest structural homolog of AfUGM in the PDB (Fig. 
2.11). PPOX has FAD binding, membrane binding, and substrate binding domains, which 
correspond to UGM domains 1, 2, and 3, respectively. PPOX (PDB code 2IVD) and 
AfUGM superimpose with a root mean square deviation of 2.5 Å covering 370 residues, 
despite sharing only 15% sequence identity. Furthermore, PPOX has some of the extra 
structural features of AfUGM that are not found in bacterial UGMs, including the 
inserted β-sheet in domain 1 and the extra helix and strand of domain 3. The significance 
of the structural homology to PPOX is not obvious.  
   
 
 
Fig. 2.11 Protoporphyrinogen oxidase from Myxococcus xanthus (PDB code 2IVD). The FAD-binding 
(blue), membrane-binding (yellow), and substrate-binding (green) domains correspond to UGM domains 1, 
2, and 3, respectively. Red indicates elements that are common to AfUGM and PPOX but not found in 
bacterial UGMs. 
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Neither oligomeric state nor quaternary structure is conserved in UGM. Dimers 
are common for bacterial UGMs, whereas AfUGM forms a tetramer in solution. UGM 
from E. coli was shown to be dimeric in solution based on dynamic light scattering40, and 
the crystal structure revealed a semicircular dimer that likely represents the dimer in 
solution36. This dimer is also found in the crystal lattices of KpUGM and Mycobacterium 
tuberculosis UGM41. DrUGM appears to have a different quaternary structure, although 
this has not been confirmed with solution studies. Analysis of the interfaces in the 
primitive orthorhombic lattice of DrUGM suggests that the enzyme forms a decamer in 
solution 37. The decamer is a pentamer of dimers in which the propagated dimer is unlike 
the semicircular dimer of the other bacterial UGMs. The DrUGM dimer is formed by 
interactions involving domains 1 and 3. The constituent dimers of the AfUGM tetramer 
are unlike any of the dimers of bacterial UGMs.  
 Unique structural features of AfUGM preclude the assembly of the dimers formed 
by bacterial UGMs. For example, if the classic UGM semicircular dimer is constructed 
from AfUGM protomers, several clashes across the dimer interface are evident. These 
clashes involve the 200s flap and the extra helix of domain 2, both of which are unique to 
AfUGM. Likewise, a hypothetical dimer built like DrUGM exhibits clashes in the four-
stranded sheet in domain 1 and the long inserted loop in domain 3. Thus, the protomer 
structure of AfUGM is incompatible with the quaternary structures of bacterial UGMs. 
 The observation of a tetramer raises the possibility of cooperativity between the 
subunits. Interestingly, previous studies have shown that 50% of the bound flavin remains 
reduced under normal laboratory conditions (absence of reducing agent), which suggests 
nonequivalence of the subunits 14. One possibility is that electrostatic repulsion between 
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reduced flavins in the tetramer could contribute to this phenomenon. FADs related by the 
P-axis are 53 Å apart, whereas those related by the Q- and R-axes are separated by 75 and 
79 Å, respectively. If electrostatic repulsion is important over the ∼50 Å scale, these 
distances suggest that protomers related by the R-axis, i.e. those along the diagonal of the 
tetramer, are equivalent. Interestingly, crystal soaking populated only the diagonal 
protomers. Future studies of cooperativity in AfUGM seem warranted.  
 The quaternary structure of AfUGM enables conformational changes that 
distinguish AfUGM from bacterial UGMs. AfUGM has two flaps that move substantially 
upon substrate binding and product release. Bacterial UGMs have just one mobile loop 
that enters the active site upon substrate binding (Fig. 2.2B, mobile loop) (37, 38). This loop 
is analogous to the 180s flap of AfUGM. The region of bacterial UGMs corresponding to 
the 200s flap also participates in substrate binding (Fig. 2.2B, static loop). In particular, 
Tyr-185 and Phe-186 of KpUGM (Tyr-209 and Phe-210 of DrUGM) contact the 
pyrophosphate and Galp moiety of UDP-Galp, respectively. However, these residues are 
static because the loop is in a protein-protein interface, and a neighboring protein 
molecule of the oligomer restricts the motion of the loop, effectively locking it in the 
closed conformation. In contrast, the 200s flap of AfUGM resides on the surface of the 
tetramer (Fig. 2.4A) and is able to adopt open and closed conformations. Thus, 
tetramerization of AfUGM allows an additional degree of conformation freedom.  
 It is notable that very few of the flap residues directly interact with the substrate. 
(Exceptions are Arg-182 and Asn-207.) This observation suggests that the purpose of flap 
closure is not only to assemble the constellation of residues needed for substrate 
recognition but also to create a protected environment for catalysis. The latter role is 
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consistent with mechanisms in which UDP is displaced during the catalytic cycle1 
because closure of the flaps presumably prevents the severed UDP from migrating out of 
the active site.  
 Finally, the AfUGM structures provide additional insight into the catalytic 
mechanism of UGM. Two prevailing mechanisms have been proposed based on studies 
of the bacterial enzymes1. One mechanism begins with the flavin functioning as a 
nucleophile that attacks the anomeric carbon of galactose to form a covalent intermediate 
and displace UDP42. The other mechanism involves single electron transfer from the 
reduced flavin to an oxocarbenium sugar intermediate followed by the formation of a 
flavin-sugar adduct (43, 44). Which of these mechanisms, if either, applies to eukaryotic 
UGMs is unknown. However, the Galp moiety in the AfUGMr-UDP-Galp complex is 
poised for nucleophilic attack by the FAD N5 at the anomeric carbon atom (Fig. 2.9A). 
Also, the direction of the bend of the FAD isoalloxazine in AfUGM is consistent with 
formation of a covalent intermediate 41. For bacterial UGMs, crystal structures, reductive 
trapping experiments, and studies with modified flavins support the covalent mechanism 
(37, 38, 44). Thus, it seems likely that bacterial and eukaryotic UGMs share a common 
catalytic mechanism. 
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Abstract 
 Chagas disease is a neglected tropical disease caused by the protozoan parasite 
Trypanosoma cruzi. Here we report crystal structures of the galactofuranose biosynthetic 
enzyme UDP-galactopyranose mutase (UGM) from T. cruzi, which are the first structures 
of this enzyme from a protozoan parasite. UGM is an attractive target for drug design 
because galactofuranose is absent in humans but is an essential component of key 
glycoproteins and glycolipids in trypanosomatids. Analysis of the enzyme–UDP 
noncovalent interactions and sequence alignments suggests that substrate recognition is 
exquisitely conserved among eukaryotic UGMs and distinct from that of bacterial UGMs. 
This observation has implications for inhibitor design. Activation of the enzyme via 
reduction of the FAD induces profound conformational changes, including a 2.3 Å 
movement of the histidine loop (Gly60-Gly61-His62), rotation and protonation of the 
imidazole of His62, and cooperative movement of residues located on the si face of the 
FAD. Interestingly, these changes are substantially different from those described 
for Aspergillus fumigatus UGM, which is 45% identical to T. cruzi UGM. The 
importance of Gly61 and His62 for enzymatic activity was studied with the site-directed 
mutant enzymes G61A, G61P, and H62A. These mutations lower the catalytic efficiency 
by factors of 10–50, primarily by decreasing kcat. Considered together, the structural, 
kinetic, and sequence data suggest that the middle Gly of the histidine loop imparts 
flexibility that is essential for activation of eukaryotic UGMs. Our results provide new 
information about UGM biochemistry and suggest a unified strategy for designing 
inhibitors of UGMs from the eukaryotic pathogens. 
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3.1 Introduction 
 
 Chagas disease (aka American trypanosomiasis) is a major global health concern1. 
The disease is caused by the protozoan parasite Trypanosoma cruzi and spread by 
triatomine insects, which carry the parasite in their gut. Chagas disease is one of several 
neglected tropical diseases, i.e., chronic infectious diseases that are prevalent in poor 
countries and underemphasized by society relative to the number of people affected. The 
disease is endemic in Latin America, and at least 10 million people worldwide are 
estimated to be infected with T. cruzi1. Infection mainly occurs through contact with the 
feces of triatomine bugs, but transmission also occurs via blood transfusions, organ 
transplants, ingestion of contaminated food, and mother-to-child1. It is estimated that 
30% of Chagas patients will develop heart damage in the late chronic stage of the disease, 
leading to death caused by arrhythmia in early adulthood1. More than 10 000 deaths occur 
annually from Chagas disease, and the burden of disease is the highest for any parasitic 
disease in the Western hemisphere (1,2). Chagas is unusual among neglected diseases in 
that it is spreading to nonendemic areas, including the United States, Canada, and Europe 
(2,3). The two drugs used for treatment, benznidazole and nifurtimox, have significant side 
effects and uncertain efficacy (4,6), and there is no vaccine available. The prevalence of the 
disease, the spread to new regions of the globe, and the lack of adequate medications 
emphasize the need for new drugs to treat Chagas disease. 
 The flavoenzyme UDP-galactopyranose mutase (UGM) has received attention 
recently as a drug design target for neglected tropical disease (7,9). UGM plays a central 
role in the biosynthesis of galactofuranose (Galf) by catalyzing the conversion of UDP-
galactopyranose (UDP-Galp) to UDP-galactofuranose (UDP-Galf) (Fig. 3.1). Galf has 
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never been found in humans but is an essential component of the cell wall and 
extracellular matrix of many pathogenic bacteria, fungi, and protozoa (8,9). 
 
       
   Fig. 3.1 Reaction catalyzed by UGM. 
 
 UGM and Galf are widely distributed in pathogenic protozoa (7,8). In particular, 
Galf is present in glycoinositolphospholipids and glycosylphosphatidylinositol anchor 
proteins of T. cruzi (10,11). In the related parasite, Leishmania major, which causes 
leishmaniasis, Galf is present in the membrane anchor of the lipophosphoglycan and in 
glycoinositolphospholipids12. These glycoconjugates are highly expressed throughout the 
life cycle of these parasites and are important for their survival and proliferation (12,14). 
Galf-containing glycoconjugates are thought to be involved in the mechanism of 
myocardiac invasion by T. cruzi 15. In Leishmania, lipophosphoglycans are essential for 
the binding and detachment of the parasite to the midgut of the vector insect and thus for 
transmission of the parasite to the human host (16,17). Furthermore, studies with 
lipophosphoglycan deletion mutants in L. major demonstrated that these glycosylated 
structures are involved in resistance to oxidative stress and evasion of the human immune 
system (16,17). Moreover, a UGM deletion mutant of L. major exhibits attenuated virulence 
7. In summary, Galf-containing molecules of protozoan parasites function in host-specific 
cell recognition, growth, and pathogenesis. Since UGM is essential for the biosynthesis 
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of Galf, inhibition of the enzyme is an attractive approach for finding new drugs for 
Chagas disease and leishmaniasis. 
 The potential for inhibitor design and the uniqueness of the chemical mechanism 
of UGM have motivated structural studies of the enzyme. Several crystal structures of 
bacterial UGMs have been determined (18-23). These structures revealed the essential UGM 
fold and provided insight into several aspects of UGM biochemistry, including the 
structural basis of substrate recognition and the catalytic mechanism. Eukaryotic UGMs 
have received less attention. We recently reported crystal structures and small-angle X-
ray scattering analysis of UGM from the pathogenic fungus Aspergillus 
fumigatus (AfUGM), which was the first structural data for any eukaryotic 
UGM24. Shortly thereafter, Sanders’ group published structures of AfUGM based on a 
different (space group P1) crystal form25. Our analysis of the data showed that AfUGM 
has several extra secondary and tertiary structural elements that are not found in bacterial 
UGMs yet are important for substrate recognition and tetramerization24. The AfUGM 
structures also revealed large conformational changes that accompany substrate binding, 
which is highly relevant for inhibitor design24.  
 As part of our ongoing studies of UGM from eukaryotic pathogens, we report 
crystal structures of oxidized and reduced T. cruzi UGM (TcUGM) complexed with the 
inhibitor UDP. Analysis of the UDP binding site suggests a common strategy for 
designing inhibitors of UGMs from eukaryotic pathogens, including T. cruzi, L. major, 
and A. fumigatus. Comparison of the structures of oxidized and reduced TcUGM reveals 
profound conformational changes induced by reduction of the FAD cofactor, which 
provides new information about the molecular mechanism of enzyme activation by 
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reducing agents. These results provide a foundation for inhibitor design and insight into 
UGM biochemistry. 
 
3.2 Materials and Methods 
3.2.1. Crystallization  
 
 TcUGM was expressed and purified as described previously26. Crystallization 
studies used TcUGM at 7–8 mg/mL in 150 mM NaCl buffered at pH 7.5 with either 50 
mM phosphate or 50 mM HEPES. Prior to crystallization, the enzyme was incubated 
with 10 mM UDP for 30 min. Crystallization experiments were performed at 20 °C using 
sitting drop vapor diffusion with the drops formed by mixing 1.5 μL each of the protein 
and reservoir solutions. Several commercially available crystallization screens were used 
to identify initial crystallization conditions. Promising conditions were obtained with 
reservoirs containing ammonium sulfate and HEPES buffer. Small yellow crystals 
appeared after 2 weeks. Larger crystals were obtained within a week via microseeding. 
The optimized crystallization reservoir contains 1.0 M ammonium sulfate, 0.5% 
poly(ethylene glycol) 8000, and 0.1 M HEPES at pH 7.5. The crystals were cryoprotected 
in 1.2 M ammonium sulfate, 0.1 M HEPES pH 7.5, and 25% glycerol before plunging 
into liquid N2. 
 The space group is P6522 with unit cell dimensions of a = 143 Å and c = 354 Å. 
Based on the method of Matthews27 and assuming 50% solvent content, the 
asymmetric unit is predicted to contain four protein molecules, which implies VM of 2.4 
Å3/Da (48% solvent). However, molecular replacement calculations show that the 
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asymmetric unit contains just two protein molecules (vide infra), which corresponds to 
74% solvent and VM of 4.8 Å3/Da. 
 Crystals of the TcUGM–UDP complex with the FAD in the reduced state were 
prepared by soaking the aforementioned crystals in 1.2 M ammonium sulfate, 0.1 M 
HEPES pH 7.5, 60 mM sodium dithionite, and 25% ethylene glycol. Once the crystals 
turned from yellow to colorless, they were flash-cooled by plunging into liquid N2. 
 
3.2.2 X-ray Diffraction Data Collection, Phasing, and Refinement 
 
 Diffraction data were collected at the Advanced Photon Source. The data set for 
oxidized TcUGM–UDP was collected at beamline 19-ID and processed using 
HKL300028. The data set for reduced TcUGM–UDP was collected at beamline 24-ID-C, 
and the data were integrated using XDS29 and scaled with SCALA30 via CCP4i31. Data 
processing statistics are listed in Table 3.1. 
 The phase problem for oxidized TcUGM–UDP was solved using molecular 
replacement as implemented in MOLREP32. The search model was derived from the 
structure of AfUGM (PDB code 3UTE24). Chainsaw was used to create a model in which 
all the side chains were pruned to the β-carbon atom. The calculations produced a 
solution having two molecules in the asymmetric unit with R-factor of 0.6 and score of 
0.3. The model was manually edited and built using COOT33 and refined using 
PHENIX34. An advanced model of oxidized TcUGM-UDP was used as the starting point 
for refinement of reduced TcUGM–UDP. Refinement statistics are listed in Table 3.1. 
We note that, for both the oxidized and reduced TcUGM–UDP structures, the two 
molecules in the crystallographic asymmetric unit are identical within experimental error. 
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Table 3.1 X-ray Diffraction Data Collection and Refinementa 
 
     
 Oxidized Reduced 
Space group P6522 P6522 
Unit cell parameters (Å) a = 143.4,  
c = 354.2 
a = 143.8,  
c = 354.4 
Wavelength (Å) 0.9791 0.9795 
Resolution (Å) 19.88 - 2.25 
(2.33 - 2.25) 
47.08 - 2.25 
(2.37 - 2.25) 
Observations 523354 841035 
Unique reflections 101725 102978 
Rmerge(I)b 0.105 (0.542) 0.089 (0.526) 
Rmeas(I)b 0.105 (0.647) 0.095 (0.566) 
Rpim(I)b 0.045 (0.278) 0.032 (0.204) 
Mean I/σ 14.1 (2.2) 17.6 (3.7) 
Completeness (%) 99.2 (100.0) 99.9 (99.8) 
Multiplicity 5.1 (5.2) 8.2 (7.3) 
No. of protein residues 939 938 
No. of protein atoms 7495 7482 
No. of FAD atoms 106 106 
No. of ligand atoms 50 50 
No. of water molecules 381 246 
Rcryst  0.183 (0.246) 0.180 (0.238) 
Rfreec 0.212 (0.298) 0.209 (0.283) 
rmsd bond lengths (Å)d 0.007 0.007 
rmsd bond angles (°)d 1.12 1.11 
Ramachandran plote   
  Favored (no. residues) 912 914 
  Allowed (no. residues) 21 18 
  Outliers (no. residues) 0 0 
Average B-factor (Å2)   
  Protein 30 32 
  FAD 23 24 
  UDP 21 25 
  Water 32 33 
Coordinate error (Å)f 0.32 0.32 
PDB code 4DSG 4DSH 
 
aValues for the outer resolution shell of data are given in parenthesis.  
bDefinitions of Rmerge, Rmeas, and Rpim can be found in Weiss {Weiss, 2001 #3422}1. 
cA common set of test reflections (5 %) was used for refinement of both structures. 
dCompared to the parameters of Engh and Huber {Engh, 1991 #980}. 
eThe Ramachandran plot was generated with RAMPAGE {Lovell, 2003 #2719}. 
fMaximum likelihood-based coordinate error estimate from PHENIX. 
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3.3 Results 
3.3.1 Overall Fold and Oligomeric State 
 
 The structures of oxidized and reduced TcUGM complexed with the inhibitor 
UDP were determined at 2.25 Å resolution (Table 3.1). These are the first structures of 
UGM from a parasitic pathogen and the second structure of a eukaryotic UGM. 
 
          
 
Fig. 3.2 Structure of TcUGM.  (A) Structure of the TcUGM monomer.  Domains 1, 2, and 3 are colored 
blue, yellow, and green, respectively.    FAD and UDP are colored gray and pink, respectively. (B) 
Superposition of TcUGM (blue, yellow, green) and AfUGM (gray).  (C) Close-up view of two helices on 
the periphery of domain 2. The view is rotated from panel B by about 90° around the horizontal axis.  
TcUGM and AfUGM are colored as in panel B. This figure and others were created with PyMOL 
{DeLano, 2002 #2088}. 
  
AfUGM is the closest structural neighbor of TcUGM in the Protein Data Bank 
(PDB). The two enzymes are 45% identical in sequence, and the two structures 
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superimpose with a root-mean-square deviation of 1.1 Å (Fig. 3.2B). Although they share 
a common overall fold, several local variations between the two structures are evident 
(Fig. 3.2B). For example, a loop of domain 1 is longer in TcUGM, whereas a loop in 
domain 3 is longer in AfUGM. The significance of these differences is not obvious. In 
contrast, other differences are substantive in that they appear to dictate the oligomeric 
state formed in solution. These include the longer α-helix in domain 2 of AfUGM and the 
additional α-helix at the C-terminus of AfUGM (Fig. 3.2B). 
 The crystal structure is consistent with TcUGM being monomeric in solution. 
Analysis of protein–protein interfaces in the crystal lattice using the PDBePISA37 
revealed no oligomers predicted to be stable in solution. Furthermore, neither the 
AfUGM tetramer nor its constituent dimers are present in the TcUGM crystal lattice. 
Moreover, none of the dimeric assemblies of bacterial UGMs are observed in the lattice. 
It is concluded that TcUGM forms a monomer in solution, which is consistent with recent 
size exclusion chromatography data26.  
 
3.3.2 Binding of UDP 
 
 The structures of TcUGM complexed with UDP were determined from crystals 
that had been grown in the presence of the inhibitor. Electron density maps clearly 
indicated that UDP is bound in the active site with full occupancy (Fig. 3.3A). The 
protein–ligand interactions are identical in the reduced and oxidized enzymes, so we will 
focus on the reduced enzyme complex. 
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Fig. 3.3  Electron density and interactions for the UDP bound to reduced TcUGM. (A) Stereographic view 
of the TcUGM active site. The cage represents a simulated annealing σA-weighted Fo - Fc omit map 
contoured at 3.0 σ. (B) Schematic diagram of protein-UDP interactions in TcUGM.  Backbone interactions 
are indicated by N in parentheses.  
  
 UDP binds at the re face of the isoalloxazine and is covered by the 170s and 200s 
flaps (Fig. 3.3A). Structures of AfUGM showed that the analogous loops move by 10 Å 
from the open to closed conformation upon UDP binding. The flaps of TcUGM–UDP are 
in the closed conformation, as expected. Although it was not possible to crystallize 
TcUGM in the ligand-free state, presumably the 170s and 200s flaps open and close as in 
AfUGM. 
 UDP forms several interactions with TcUGM (Fig. 3.3B). The uracil ring is 
wedged between the aromatic rings of Tyr100 and Phe152, which positions the base to 
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form three hydrogen bonds with the side chain of Gln103 and backbone of Phe102. Thus, 
the hydrogen-bonding potential of uracil is fully satisfied. The ribose hydroxyl groups of 
UDP interact with Asn157 and Trp161. The pyrophosphate directly interacts with Arg327 
and three tyrosine residues (317, 395, and 429). Several water-mediated hydrogen bonds 
are also observed. In summary, all three chemical groups of UDP—base, ribose, and 
pyrophosphate—are in direct electrostatic contact with the enzyme, which results in a 
plethora of stabilizing interactions. 
 
3.3.2 Conformational Changes Induced by FAD Reduction 
 
 The FAD of UGM functions as a nucleophile that attacks the anomeric carbon 
atom of the galactose moiety (C1 in Fig. 3.1) in an SN2-like reaction; thus, enzymatic 
activity requires that the FAD be in the reduced state (FADH–) (26,38,39). Structures of 
oxidized and reduced TcUGM were determined to understand the mechanism by which 
the enzyme is activated by FAD reduction. 
 The structure of the oxidized enzyme was determined from crystals that were 
grown and cryoprotected without reducing agent. These crystals were yellow, which is 
characteristic of the oxidized state of FAD. The structure of the reduced enzyme was 
determined from crystals of the oxidized enzyme that were soaked in reducing agent 
(dithionite) prior to flash-cooling in liquid nitrogen. The crystals turned colorless during 
soaking, which indicated that the FAD was reduced. 
 Reduction of the FAD causes substantial conformational changes in the active site 
(Fig. 3.4). In the oxidized enzyme, the conserved histidine loop (Gly60-Gly61-His62) 
adopts an unprecedented conformation for UGMs in which it is retracted from the FAD 
isoalloxazine (Fig. 3.4A). This conformation is stabilized by hydrogen bonds between 
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Asp58 and the backbone of Gly61 and His62. Upon reduction, the histidine loop shifts 
2.3 Å toward the isoalloxazine (Fig. 3.4B). In this conformation, the carbonyl of Gly61 
accepts a hydrogen bond from the flavin N5, which is a hydrogen bond donor in the 
reduced state. This hydrogen bond is observed in all reduced UGM structures and is thus 
thought to be essential for stabilizing the reduced flavin. Movement of the histidine loop 
toward the reduced flavin triggers other conformational changes (Fig. 3.4C). Asp58 and 
Thr212 rotate to engage each other in a hydrogen bond. Note that the rotation of Asp58 
also allows a hydrogen bond with Ser 48. Finally, Met347 moves into the space vacated 
by Gly61 and Asp58, while Gln434 rotates away from His62. 
 The imidazole ring of His62 becomes protonated and flips by 180° upon flavin 
reduction. Although the protonation state and value of χ2 of histidine cannot be 
determined solely from electron density at 2.25 Å resolution, these attributes can be 
inferred from hydrogen-bonding considerations and knowledge of the preferred tautomer 
of neutral histidine. Analysis of hydrogen bonding with MolProbity40 suggests that in the 
oxidized enzyme, His62 adopts the neutral τ tautomer with the imidazole accepting a 
hydrogen bond from Gln434 and donating a hydrogen bond to the carbonyl of Leu59 
(Fig. 3.4A). We note that τ is the preferred tautomer of neutral His41. In the reduced 
enzyme, on the other hand, hydrogen bonding is maximized with the imidazole 
protonated and flipped by 180° to allow hydrogen bonds with the carbonyl of Gly60 and 
the FAD 2′-hydroxyl (Fig. 3.4B). Note that the assigned protonation states of His62 are 
consistent with the fact that the oxidized FAD is uncharged and the reduced FAD is 
anionic (FADH–). 
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Fig. 3.4 Structural changes induced by FAD reduction.  (A) Electron density for the histidine loop region of 
oxidized TcUGM.  The cage represents a simulated annealing σA-weighted Fo - Fc omit map contoured at 3 
σ.  (B) Electron density for the histidine loop region of reduced TcUGM.  The cage represents a simulated 
annealing σA-weighted Fo - Fc omit map contoured at 3 σ.  (C) Superposition of oxidized (yellow) and 
reduced (gray) TcUGM. Red and black dashes represent hydrogen bonds for oxidized and reduced 
TcUGM, respectively.  
 
 
 Reduction also affects the conformation of the isoalloxazine (Fig. 3.5). In the 
oxidized state, the electron density maps are consistent with a planar isoalloxazine (Fig. 
3.5A). In the reduced enzyme, the FAD exhibits a butterfly like conformation in which 
the pyrimidine ring bends 7° out of the plane such that the si face is concave (Fig. 3.5A). 
This conformation is identical to that of reduced AfUGM. 
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Fig. 3.5 Electron density for the isoalloxazine rings of (A) oxidized and (B) reduced TcUGM.  The cages 
represent simulated annealing σA-weighted Fo - Fc omit maps contoured at 3 σ.  The horizontal line assists 
in seeing the 7° butterfly-like bend angle of the reduced cofactor. 
 
 
 
3.3.3 Site-Directed Mutagenesis of the Histidine Loop 
 
 The importance of the histidine loop for catalytic activity was investigated using 
site-directed mutagenesis. Gly61 and His62 were targeted for mutagenesis because they 
form hydrogen bonds to FADH– and exhibit large conformational changes upon flavin 
reduction. Gly61 is conserved among eukaryotic UGMs but appears as Ala or Pro in 
bacterial UGMs. Therefore, the mutant enzymes G61A and G61P were created. His62 is 
universally conserved among UGMs, and the H62A mutant enzyme was created. (For 
reference, Gly60 is also conserved in all UGMs.) 
 Mutation of the histidine loop of TcUGM is highly detrimental to activity (Fig. 
3.6 and Table 3.2). Mutation of Gly61 to Ala reduces kcat by a factor of 70 but 
reduces Km by only a factor of 3. As a result, the catalytic efficiency of G61A is only 4% 
of that of TcUGM. Similarly, mutation of Gly61 to Pro substantially decreases kcat (factor 
of 16) but has less effect on Km. The catalytic efficiency of this mutant enzyme is 10% of 
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that of TcUGM. Mutation of His62 to Ala has a profound effect on kcat; this mutation 
decreases kcat by over 300. The catalytic efficiency of H62A is just 2% compared to that 
of TcUGM. These results suggest that Gly and His at positions 61 and 62 are important 
for efficient catalysis by TcUGM. Furthermore, the histidine loop sequences found in 
bacterial UGMs (GAH, GPH) are poorly tolerated by TcUGM. 
 
 
  Fig. 3.6 Superposition of the active sites of TcUGM and AfUGM. 
 
 
Table 3.2 Steady-state kinetic constants for TcUGM and TcUGM mutant enzymes. 
 
 kcat (s-1) Km (mM) kcat (s-1)/Km 
(s-1 M-1) 
kcat (s-1)/Km 
(%) 
TcUGM 13.4 ± 0.3 140 ± 10 93 ± 6 100 ± 6 
G61A 
0.198 ± 0.011 50 ± 10 4 ± 1 4 ± 1 
G61P 
0.83 ± 0.06 90 ± 20 9 ± 2 10 ± 2 
H62A 
0.041 ± 0.001 24 ± 4 1.8 ± 0.2 2 ± 0.2 
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3.4 Discussion 
 
 Inhibitor design is aided by knowledge of substrate recognition, and substrate 
recognition appears to be exquisitely conserved among eukaryotic UGMs. Comparison of 
the structures of TcUGM and AfUGM complexed with UDP show that the UDP binding 
sites are identical (Fig. 3.7). All residues that contact UDP, either directly or via water 
molecules, are present in both enzymes. Furthermore, the conformations of these 
residues, as well as their interactions with UDP, are identical in the two structures. The 
structural similarity extends even to the water molecules that mediate protein–inhibitor 
interactions (Fig. 3.7). Moreover, all residues that contact UDP or UDP-Galp in the 
TcUGM and AfUGM crystal structures are also present in many other eukaryotic UGMs, 
including L. major UGM (Fig. 3.7, triangles). Thus, it is likely that the AfUGM and 
TcUGM structures are representative of eukaryotic UGMs with regard to substrate 
binding. 
 The TcUGM structures provide new information about conformational changes 
associated with activation of the enzyme via reduction of the FAD (Fig. 3.4 and 3.5). 
Reduction of the FAD causes several concerted changes in the protein. The histidine loop 
moves by 2.3 Å (Fig. 3.4C). His62, a universally conserved residue in UGMs, flips by 
180° and becomes protonated. The protonation of His62 may help stabilize the negative 
charge of the reduced FAD. The side chains of Asp58 and Thr212 rotate by 180°. Met 
347 and Gln434 move by 1.6 Å. It is notable that all of these residues are located on the 
side of the FAD that is opposite to the substrate-binding site. Thus, two critical aspects of 
function are delegated to distinct regions of the protein: maintaining the redox state is the 
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responsibility of residues on the si face FAD, while substrate binding is performed by 
residues on the re side. 
 
 
 
Fig. 3.7 Amino acid sequence alignment of UGMs from T. cruzi, L. major, and A. fumigatus.  The 
secondary structure elements above and below the alignment are from the TcUGM and AfUGM structures, 
respectively.  The yellow box denotes the histidine loop, which moves in response to changes in the FAD 
redox state.  The green triangles denote residues that contact UDP-Galp; note that they are 100 % identical 
in the three enzymes. 
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 These conformational changes are consistent with the generally accepted 
chemical mechanism of UGM. The prevailing mechanism is an SN2-type displacement in 
which the N5 atom of the reduced FAD functions as the nucleophile that attacks the 
anomeric carbon of galactose to form a covalent intermediate and displace UDP (38,39). 
This mechanism was recently validated for TcUGM26. Activity thus requires that the 
FAD be reduced. The coordinated movements of the histidine loop, Asp58, Thr212, and 
the FAD isoalloxazine in TcUGM have two salient effects. First, a hydrogen bond is 
created between the N5 atom of the reduced flavin and the carbonyl oxygen atom of the 
residue preceding the conserved histidine (Gly61). This interaction is seen in all reduced 
UGMs and is therefore thought to be essential for stabilizing the reduced flavin. Second, 
curvature is induced in the flavin isoalloxazine such that the si face is concave. Bending 
of the isoalloxazine in this direction is consistent with the FAD functioning as a 
nucleophile 19.  
 Curiously, the conformational changes observed for TcUGM are different from 
those described for the close homologue AfUGM (Fig. 3.8). We previously reported 
structures of oxidized and reduced AfUGM based on a P6522 crystal form24. Sanders’ 
group subsequently reported P1 structures of AfUGM25. The structures of the reduced 
active sites are nearly identical in TcUGM and AfUGM (Fig. 3.8C). However, in 
oxidized AfUGM, the His residue of the histidine loop is substantially displaced toward 
the pyrimidine portion of the isoalloxazine (Fig. 3.8B), whereas in oxidized TcUGM the 
His residue is near the middle ring of the isoalloxazine (Fig. 3.8A). Furthermore, in 
oxidized AfUGM, the carbonyl bond vector of the middle Gly residue is directed away 
from the isoalloxazine (Fig. 3.8B, Gly62), whereas the corresponding carbonyl of 
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oxidized TcUGM points toward the isoalloxazine (Fig. 3.8A, Gly61). Reduction of the 
FAD in AfUGM causes a 6–8 Å movement of the imidazole ring of the conserved 
histidine (Fig. 3.8). As described above, the movement of the histidine loop in TcUGM is 
more subtle. It should be noted that elucidation of redox-linked conformational changes 
for AfUGM is complicated by the adventitious binding of sulfate ions to the oxidized 
active site of the P6522 crystal form (PDB code 3UTE) and weak electron density for the 
histidine loop and bound UDP in the oxidized P1 form (3UKH). Nevertheless, taken 
together, the AfUGM and TcUGM structures implicate flexibility of the histidine loop in 
the mechanism of enzyme activation. 
 
 
Fig. 3.8 Summary of conformational changes induced by flavin reduction in TcUGM and AfUGM. (A) 
Oxidized TcUGM (PDB code 4DSG).  (B) Oxidized AfUGM crystallized in space groups P6522 (cyan, 
PDB code 3UTE) and P1 (yellow, PDB code 3UKH). (C) Superposition of reduced TcUGM (gray, 4DSH) 
and reduced AfUGM (green, 3UTF). 
 
 The large conformational changes in the histidine loop observed in TcUGM and 
AfUGM appear to be unique to eukaryotic UGMs. Comparison of oxidized and reduced 
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bacterial UGM structures shows that flavin reduction induces bending of the 
isoalloxazine but no substantial changes in the protein conformation (19,21,22). nalysis of 
amino acid sequence conservation provides a rationale for why the histidine loop is static 
in bacterial UGMs and dynamic in eukaryotic UGMs. The histidine loop sequence of 
GGH is conserved among eukaryotic UGMs (Fig. 3.8). In contrast, bacterial UGMs have 
either Ala or Pro in place of the second Gly. The extra Gly in the histidine loop most 
likely accounts for the increased flexibility of the loop in AfUGM and TcUGM. 
 This additional flexibility of the histidine loop appears to be important for 
function in TcUGM. Our mutagenesis data show that transplanting the bacterial 
sequences of GAH and GPH into TcUGM substantially decreases catalytic efficiency 
(Table 3.2). It is possible that the additional flexibility afforded by the extra Gly residue 
in TcUGM is needed to establish optimal hydrogen bonding between the histidine loop 
and FADH–. Although structures of the TcUGM histidine loop mutant enzymes are not 
available, it is possible that the loop-flavin hydrogen bonding is suboptimal in these 
impaired enzymes, which likely decreases the nucleophilic character of the reduced 
flavin. This idea is consistent with the markedly decreased kcat values of the histidine loop 
mutants. 
 Why eukaryotic UGMs undergo such large conformational changes upon 
activation is an open question. One possibility is that these conformational changes 
control the access of O2 and reductant to the flavin. In the reduced enzyme, positioning 
the histidine loop close to the isoalloxazine N5–C4a edge helps protect the C4a atom of 
the reduced FAD from attack by O2 (Fig. 3.4B). Retraction of the loop upon oxidation 
perhaps allows open space for reducing agents to gain access to the oxidized flavin (Fig. 
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3.4A). Regulation of function is another possibility. Conformational changes that are 
linked to the flavin redox state often serve a regulatory purpose42. Whether eukaryotic 
UGMs are subject to some sort of redox-linked regulation remains to be determined. 
 
    
Fig. 3.9 Structure of the AfUGM tetramer.  (A) The tetramer is viewed down the R molecular 2-fold axis.  
Each chain has a different color. Inset: Intersubunit hydrogen bonds formed by Arg133 at the intersection 
of molecular 2-fold axes. (B) The tetramer is viewed down the Q-axis. 
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Abstract 
 UDP-galactopyranose mutase (UGM) plays an essential role in galactofuranose 
biosynthesis in microorganisms by catalyzing the conversion of UDP-galactopyranose to 
UDP-galactofuranose.  The enzyme has gained attention recently as a promising target 
for the design of new antifungal, antitrypanosomal, and antileishmanial agents. Here we 
report the first crystal structure of UGM complexed with its redox partner NAD(P)H.  
Kinetic protein crystallography was used to obtain structures of oxidized Aspergillus 
fumigatus UGM (AfUGM) complexed with NADPH and NADH, as well as reduced 
AfUGM after dissociation of NADP+.  NAD(P)H binds with the nicotinamide near the 
FAD isoalloxazine and the ADP moiety extending toward the mobile 200s active site 
flap. The nicotinamide riboside binding site overlaps that of the substrate galactopyranose 
moiety, thus NADPH and substrate binding are mutually exclusive. On the other hand, 
the pockets for the adenine of NADPH and uracil of the substrate are distinct and 
separated by only 6 Å, which raises the possibility of designing novel inhibitors that bind 
both sites. All twelve residues that contact NADP(H) are conserved among eukaryotic 
UGMs.  Residues that form the AMP pocket are absent in bacterial UGMs, which 
suggests that eukaryotic and bacterial UGMs have different NADP(H) binding sites.  The 
structures address the longstanding question of how UGM binds NAD(P)H and provide 
new opportunities for drug discovery. 
 
 
 
 
 75 
4.1 Introduction 
 
 UDP-galactopyranose mutase (UGM) catalyzes the conversion of UDP-
galactopyranose (UDP-Galp) to UDP-galactofuranose (UDP-Galf), which is a central step 
in Galf biosynthesis (Fig. 4.1A)1. The enzyme has attracted interest as a drug target 
because Galf is an essential building block of the cell wall and extracellular matrix of 
many bacteria, fungi, and protozoa, but Galfand UGM are absent in humans. In 
particular, eukaryotic UGMs have emerged recently as targets for the design of 
antifungal, antitrypanosomal, and antileishmanial agents (2-4). For example, gene deletion 
studies have shown that UGM is essential for the virulence of the pathogenic 
fungus Aspergillus fumigatus and the protozoan parasite Leishmania major (5,6). Thus, 
there is interest in characterizing the ligand binding sites of UGMs to facilitate drug 
discovery. 
 
   
 
Fig. 4.1 (A) Reaction catalyzed by UGM. (B) Catalytic scheme indicating the PDB codes of AfUGM 
crystal structures. Asterisks denote the structures reported here. 
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 UGM is an atypical flavoenzyme in that it does not catalyze an oxidation–
reduction reaction, and thus the flavin redox state is unchanged by the transformation of 
substrate to product 7. Rather than serving as a redox center, the flavin cofactor in UGM 
is a nucleophile that attacks the anomeric carbon atom of the substrate (C1 in Fig. 4.1A) 
(8-10). The role as nucleophile requires that the flavin be reduced (FADH–) in the resting 
state of the enzyme. 
 The requirement of FADH– in UGM raises the question of what is the 
physiological reductant of the enzyme. Reduced nicotinamide adenine dinucleotides 
(NAD(P)H) are logical candidates because of their ubiquity in biology and known 
reactivity with a multitude of flavoenzymes, including flavin reductases and flavin 
monooxygenases11. Indeed, early studies showed that NADPH and NADH reduce UGM 
from Klebsiella pneumoniae, albeit relatively slowly (12,13). More recently, we showed that 
NADPH and NADH are effective redox partners of Trypanosoma cruzi UGM (TcUGM) 
10. These studies suggest that reduced nicotinamide adenine dinucleotides may be the 
physiological reductant of some UGMs. However, an NAD(P)H binding motif is not 
evident in UGM sequences, and the location of the NAD(P)H binding site has remained 
elusive despite the availability of dozens of crystal structures of bacterial (14-19) and 
eukaryotic (20-22) UGMs. To address this outstanding issue of UGM biochemistry, we have 
determined the crystal structures of UGM from the pathogenic fungus Aspergillus 
fumigatus (AfUGM) complexed with NADPH and NADH. 
 
4.2 Materials and Methods 
4.2.1 Crystal Soaking Experiments 
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 Methods for the crystallization of oxidized AfUGM have been described20. 
Kinetic protein crystallography26 as used to determine structures of oxidized AfUGM 
(AfUGMo) complexed with NADPH or NADH and of reduced AfUGM (AfUGMr) after 
dissociation of NADP+. The soaking time and reductant concentration were varied to find 
appropriate soaking conditions. The AfUGMo-NAD(P)H complexes were obtained by 
soaking the crystals for 1 min in cryobuffer (1.4 M ammonium sulfate, 0.1 M sodium 
acetate, and 25% ethylene glycol at pH 4.5) containing 120–140 mM NADPH or NADH 
prior to flash-cooling in liquid nitrogen. The crystals remained yellow during this 
relatively short soaking time, which is consistent with the oxidized state of the FAD. The 
structure of AfUGMr without NADP+ bound was determined from a crystal soaked for 30 
min in the cryobuffer containing 100 mM NADPH. Over this time scale, the yellow color 
was completely bleached, which is indicative of full reduction of the crystalline enzyme. 
 
4.2.2 X-ray Diffraction Data Collection and Refinement 
 
 Diffraction data were collected on beamlines 24-ID-C and 24-ID-E of the 
Advanced Photon Source. The data were integrated using XDS27 and scaled with 
SCALA28. Data processing statistics are listed in Table 4.1. 
 Crystallographic refinement calculations were initiated from coordinates derived 
from the 2.25 Å resolution structure of AfUGM (Protein Data Bank (PDB) code 3UTF). 
These calculations were performed with PHENIX29, and the B-factor model consisted of 
an isotropic B-factor for each atom and TLS refinement using one TLS group per protein 
chain. NCS restraints were used in the refinement of the 2.75 Å resolution structures. 
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Table 4.1 X-ray Diffraction Data Collection and Refinementa 
 AfUGMo-NADPH AfUGMo-NADH AfUGMr 
Data collection 
Soaking ligand NADPH NADH NADPH 
Soaking time (min.) 1 1 30 
Flavin redox state Oxidized Oxidized Reduced 
Space group P6522 P6522 P6522 
Unit cell parameters (Å) a =218.3, c = 319.2 a =218.3, c = 318.1 a = 217.4, c = 319.9 
Wavelength (Å) 0.979 0.979 0.979 
Resolution (Å) 163-2.75 (2.90-2.75) 162-2.75 (2.90-2.75) 50-2.20 (2.32-2.20) 
Observations 851567 982507 984169 
Unique reflections 116001 115207 222394 
Rmerge(I)b 0.137 (0.885) 0.158 (1.216) 0.093 (0.673) 
Rmeas(I)b 0.147 (0.967) 0.168 (1.297) 0.106 (0.778) 
Rpim(I)b 0.054 (0.382) 0.054 (0.429) 0.049 (0.383) 
Mean I/σ 11.6 (2.2) 10.9 (2.1) 9.8 (2.0) 
Completeness (%) 99.9 (99.9) 99.6 (99.9) 99.7 (99.8) 
Multiplicity 7.3 (6.1) 8.5 (7.9) 4.4 (4.0) 
Refinement 
Resolution (Å) 163-2.75 (2.78-2.75) 162-2.75 (2.78-2.75) 48-2.20 (2.28-2.20) 
No. of protein residues 1987 1989  2017 
No. of protein atoms 15008 15164 15526 
No. of FAD atoms 212 212 212 
No. of NAD(P)H 
molecules/atoms 
4/158 2/88 0/0 
NAD(P)H occupancyc 0.7-0.9 0.9 - 
No. of water molecules 16 26 435 
Rcryst  0.210 (0.299) 0.212 (0.404) 0.201 (0.293) 
Rfreed 0.246 (0.318) 0.245 (0.391) 0.227 (0.343) 
rmsd bond lengths (Å)e 0.008 0.008 0.007 
rmsd bond angles (°)e 1.17 1.19 1.05 
Ramachandran plotf    
  Favored (no. residues) 1908 1919 1978 
  Allowed (no. residues) 59 50 31 
  Outliers (no. residues) 0 0 0 
Average B-factor (Å2)    
  Protein 53 51 41 
  FAD 52 53 37 
  NAD(P)Hc 48-72 50-52 - 
  Water 36 41 37 
Coordinate error (Å)g 0.41 0.51 0.36 
PDB code 4gdc 4gdd 4gde 
 
aValues for the outer resolution shell of data are given in parenthesis.  
bDefinitions of Rmerge, Rmeas, and Rpim can be found in Weiss.{Weiss, 2001 #3255} 
cRange reflects the ligands bound to different chains of the tetramer. 
dA common set of test reflections (5 %) was used for refinement of all structures. 
eCompared to the parameters of Engh and Huber.{Engh, 1991 #980} 
fThe Ramachandran plot was generated with RAMPAGE.{Lovell, 2003 #2719} 
gMaximum likelihood-based coordinate error estimate from PHENIX. 
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COOT was used for model building30. The ligand occupancy (q) was estimated by 
inspecting the ligand B-factors after refinements performed with the ligand occupancy 
fixed at various values. Refinement statistics are listed in Table 4.1.  
 
4.2.3 Mutagenesis and Kinetics 
 
 Site-directed mutants of AfUGM were created using the QuikChange Site-
Directed Mutagenesis Kit (Stratagene) following the protocol supplied by the 
manufacturer. All mutant enzymes were expressed and purified following the procedures 
for AfUGM31.  
 AfUGM and AfUGM mutant enzymes were analyzed using stopped-flow kinetics 
experiments as described previously for TcUGM10. In these experiments, the enzyme and 
NAD(P)H were mixed under anaerobic conditions at 15 °C and pH 7.0, and the reaction 
was monitored using the flavin absorbance at 452 nm. The time course of the absorbance 
was fit to a single exponential to obtain an observed rate constant, kobs. Kinetic parameters 
for the reduction of the enzyme by NAD(P)H were obtained by fitting the kobs values to 
the equation, kobs =kred[NAD(P)H]/(Kd + [NAD(P)H]), where kred is the rate constant for 
flavin reduction, and Kd is the dissociation constant for NAD(P)H.  
 
4.3 Results 
4.3.1 Kinetics of Enzyme Activation by NAD(P)H 
 
 We first established that NAD(P)H reduces AfUGM (Table 4.2). The rate 
constant for reduction (kred) by NADPH is 3 s–1, and the dissociation constant for NADPH 
(Kd) is 25 μM. The catalytic efficiency for NADPH is thus 120,000 M–1 s–1, which is 20 
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times higher than that of TcUGM10 (kred = 0.6 s–1, Kd = 98 μM, kred/Kd = 6000 M–1 s–1). The 
kinetic constants for the reaction of AfUGM with NADH are kred of 0.2 s–1 and Kd of 260 
μM (kred/Kd = 670 M–1 s–1). These results show that NAD(P)H activates AfUGM in 
vitro and that AfUGM, like TcUGM, exhibits a preference for NADPH. 
 
Table 4.2 Kinetic Parameters for the Reduction of AfUGM Mutant Enzymes by 
NAD(P)H. 
 
 
kred (s-1) Kd (μM) kred/Kd (M-1 s-1) 
Variational Effect  
(kred/Kd of 
variant)/(kred/Kd of 
AfUGM) 
NADPH 
AfUGM 2.98 ± 0.078 25 ± 2 120000 ± 10000  
R447A 0.00240 ± 0.00007 39 ± 6 60 ± 10 0.0005 ± 0.0001 
R91A 0.313 ± 0.008 330 ± 20  980 ± 70 0.008 ± 0.001 
S93A 0.17 ± 0.01 21 ± 8 8000 ± 3000 0.07 ± 0.03 
Y317A 3.36 ± 0.09 100 ± 10 34000 ± 3000 0.28 ± 0.03 
Y104A 2.20 ± 0.04 54 ± 4 41000 ± 3000 0.34 ± 0.04 
NADH 
AfUGM 0.172 ± 0.003 260 ± 20 670 ± 50  
 
 
The stereochemistry of hydride transfer for AfUGM was determined using KIE 
measurements (Table 4.3). When the pro-R H atom was substituted with D, KIE values 
on flavin reduction of 3.0 ± 0.1 and 6.0 ± 0.7 were observed for NADPH and NADH, 
respectively. In contrast, a KIE value of 0.93 ± 0.03 was measured when pro-S NADPD 
was used to reduce AfUGM. These results show that the pro-R hydride of NADPH is 
 81 
transferred to AfUGM. KIE measurements also indicate pro-R stereochemistry for 
TcUGM (Table 4.3).  
 
Table 4.3 Deuterium Kinetic Isotope Effects for Hydride Transfer to AfUGM and 
TcUGMa.  
 
 AfUGM TcUGM 
NADPH 3.0  ± 0.1 1.85 ± 0.01 
NADH 6.0 ± 0.7 3.9 ± 0.2 
 
aexpressed as the ratio of kred measured using [4R-4-2H]-NAD(P)H to kred measured using NAD(P)H 
 
 
4.3.2 NAD(P)H Binding Site 
 
 Kinetic protein crystallography26 was used to obtain structures of AfUGM 
relevant to enzyme activation by NADP(H) (Fig. 4.1B). Short soaks (<1 min) of crystals 
in 100 mM NAD(P)H followed by freeze-trapping in liquid nitrogen yielded 2.75 Å 
resolution structures of the oxidized enzyme (AfUGMo) complexed with NADPH and 
NADH. The two structures are very similar and have a root-mean-square deviation 
(RMSD) of 0.31 Å for the Cα atoms of the tetramer. The pairwise RMSDs for the 
individual chains of the two structures span the range 0.17–0.51 Å. 
 Electron density maps clearly indicated the presence of NADPH bound in the 
active site (Fig. 4.2B). The occupancy of NADPH varied among the protomers of the 
tetramer, with the strongest density appearing in chains A and B. We note that this 
pattern of differential ligand occupancy (high in protomers A and B, low in protomers C 
and D) was observed in our studies of substrate and inhibitor binding to AfUGM, which 
also involved soaking the P6522 crystal form used here20. The maps allowed the building 
of complete models of NADPH at nearly full occupancy (q = 0.9) in chains A and B 
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(Fig. 4.2B). In chains C and D of the tetramer, the density was strong for the ADP group 
but weaker for the nicotinamide riboside group. Therefore, only the ADP part of NADPH 
(q = 0.7) was modeled in chains C and D.  
 
 
Fig. 4.2 Crystal structure of AfUGMo complexed with NADPH. (A) Protomer structure. FAD and NADPH 
are colored yellow and pink, respectively. Domains 1, 2, and 3 are colored blue, yellow, and green, 
respectively. (B) Stereographic view of the NADPH binding site. The cage represents a simulated 
annealing σA-weighted Fo − Fc omit map (3.0 σ). Prior to calculating the map, NADPH was omitted and 
simulated annealing refinement was performed. 
 
 
 Strong density was also observed for NADH (Fig. 4.3). As in the AfUGMo-
NADPH structure, differential ligand occupancy was evident. Complete models of 
NADH were built at q = 0.9 in chains A and B, while NADH was omitted in chains C 
and D. 
NAD(P)H binds to AfUGMo at the intersection of the three protein domains with 
the nicotinamide near the re face of the isoalloxazine and the rest of the dinucleotide 
directed toward the 200s substrate-binding flap (Fig. 4.2A). The nicotinamide riboside 
binding site overlaps that of the Galp moiety of the substrate (Fig. 4.4A), and thus 
NAD(P)H and substrate binding are mutually exclusive. This result is expected since 
both NAD(P)H and UDP-Galp require access to the flavin N5 atom at the re face of the 
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isoalloxazine. On the other hand, the AMP group of NAD(P)H and the UMP group of the 
substrate bind in different pockets on either side of Tyr104 (Fig. 4.4A). 
 
 
 
Fig. 4.3 The active site of AfUGMo-NADH (stereographic views).  (A) Electron density of NADH. FAD 
and NADH are colored yellow and pink, respectively, and the cage represents a simulated annealing σA-
weighted Fo - Fc omit map contoured at 3.0 σ.  Prior to calculation of the map, NADH was omitted and 
simulated annealing refinement was performed. (B) Superposition of AfUGMo-NADH (green) and 
AfUGMo-NADPH (white).   
  
 NAD(P)H forms several interactions with AfUGMo (Fig. 4.2B and Fig. 4.3). The 
adenosine moiety occupies a hydrophobic pocket formed by Ile65, Phe66, Tyr104, and 
the nonpolar part of the side chain of Arg91. The latter residue serves as the floor of the 
adenosine binding pocket along with the main chain of Ile92 and the side chain of Ser93. 
The adenine base forms hydrogen bonds with Ser93 and Tyr317. Tyr104 of the pocket 
makes a hydrogen bond with the 2′-phosphoryl of NADPH. This side chain is rotated 
slightly in the NADH complex because of the absence of the 2′-phosphoryl in NADH 
(Fig. 4.3B). Otherwise, the binding sites of the NADPH and NADH complexes are 
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identical within experimental error (Fig. 4.3B). The pyrophosphate is stabilized by 
electrostatic interactions with His68 and Asn457. Finally, the nicotinamide ring is 
wedged between Tyr453 and Asn457, and its carboxamide forms hydrogen bonds with 
Arg447 and Tyr419. 
 
    
Fig. 4.4 Spatial proximity of the NADPH and substrate binding sites (stereographic views). In both panels, 
the view is from the outside of the enzyme looking into the active site. (A) Active site surface of AfUGMo-
NADPH. FAD and NADPH are colored yellow and pink, respectively. For reference, the AfUGMo-
NADPH structure has been overlaid with the AfUGMr-UDP-Galp complex (PDB code 3UTH20) and the 
UDP-Galp (green) included in this image. The dashed yellow line denotes the 6.3 Å distance between the 
adenine and uracil sites. (B) Active site surface of AfUGMr. For reference, the AfUGMo- NADPH 
structure has been overlaid with AfUGMr and the NADPH (pink) included in this image.  
  
 The nicotinamide is not optimally aligned for hydride transfer in the AfUGMo-
NADPH and AfUGMo-NADH complexes. For reference, glutathione reductase, which 
also binds FAD using a Rossmann fold domain, demonstrates the expected orientation of 
the nicotinamide relative to the isoalloxazine (PDB code 1GRB)32. In glutathione 
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reductase, the nicotinamide stacks in parallel with the middle ring of the isoalloxazine 
such that the hydride transfer partners, C4 of NADPH and N5 of FAD, are separated by 
3.2 Å. In AfUGM, the nicotinamide and isoalloxazine rings are not parallel, and the C4–
N5 distance is 5.8 Å (Fig. 4.2B and Fig. 4.3). The observed arrangement of the hydride 
transfer partners may result from the adventitious binding of a sulfate ion in the active 
site (Fig. 4.2B and Fig. 4.3). Alternatively, the observed complex could represent a 
transient species that precedes the active hydride transfer complex. This possibility is 
supported by the observation that the 30-min soak in NADPH generated the reduced 
enzyme with the dinucleotide dissociated (vide infra), implying that NADPH moves from 
the observed conformation to the active one. Baeyer–Villiger monooxygenases provide 
precedent for this phenomenon, which is known as the “sliding cofactor” model (33-34).  
 Guided by the constraint of pro-R stereochemistry determined from KIE 
measurements, we generated a model of the hydride transfer complex. Using only 
dihedral angle rotations and keeping the ADP fixed, it was possible to bring the re face of 
the nicotinamide in contact with the isoalloxazine such that the hydride transfer partners 
are separated by 3.1 Å (Fig. 4.5). 
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Fig. 4.5 Two views of the model of the hydride transfer complex between NADPH and AfUGMo.  NADPH 
from the crystal structure is colored pink, and the model is shown in white.  The model was created by 
manual torsional adjustment of the nicotinamide riboside moiety in COOT to bring the re face of the 
nicotinamide in contact with the FAD isoalloxazine, which is consistent with kinetic isotope effect data 
implicating pro-R stereochemistry.   
 
4.3.3 Assignment of the Flavin Redox State 
 
 As described previously, the conformations of oxidized and dithionite-reduced 
AfUGM are dramatically different, and these structural differences can be used to deduce 
the flavin redox state in lieu of microspectrophotometry (20-22). Briefly, the oxidation state 
of the FAD can be deduced from the conformation of the conserved histidine loop 
(Gly61-Gly62-His63), the identity of the hydrogen-bonding partner of the flavin N5 
(Arg327 for FAD, Gly62 for FADH–), the orientation of Trp315, and the curvature of the 
isoalloxazine (planar for FAD, bent by 7° for FADH–). 
 To establish the conformation of the NADPH-reduced enzyme, the 2.2 Å 
resolution structure of AfUGM was determined from a crystal of the oxidized enzyme 
that had been soaked for 30 min in 100 mM NADPH. The yellow color of the crystal was 
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completely bleached, which is indicative of full reduction of the crystalline enzyme. The 
NADPH-reduced and dithionite-reduced (PDB code 3UTF) structures are very similar 
(RMSD = 0.24 Å). Furthermore, the structural indicators of the flavin redox state in all 
four chains of the NADPH-reduced enzyme are consistent with the reduced flavin state. 
In particular, His63 is located on the si face of the isoalloxazine, where it forms hydrogen 
bonds with Gly61 and the ribityl chain (Fig. 4.6A). Furthermore, Gly62 accepts a 
hydrogen bond from the flavin N5 atom. This interaction is diagnostic of the reduced 
flavin because the main chain carbonyl is an obligate hydrogen bond acceptor, and N5 is 
a donor only in the reduced state. Lastly, at 2.2 Å resolution it is possible to discern the 
7° bend of the isoalloxazine (Fig. 4.6A). All of these structural features are also observed 
in the structure of dithionite-reduced AfUGM, as shown by an overlay of the NADPH-
reduced and dithionite-reduced active sites (Fig. 4.6A). 
 The structural indicators of the redox state clearly show that the flavin is oxidized 
in the NAD(P)H complexes. At 2.75 Å resolution, it is difficult to discern the curvature 
of the isoalloxazine, so the protein conformation is a better indicator of the flavin redox 
state. In particular, His63 is near the pyrimidine portion of the isoalloxazine and oriented 
parallel to Trp315 (Fig. 4.6B). As noted by van Straaten et al.22, this particular 
arrangement of these two side chains occurs in AfUGMo. We note that the position of 
His63 in AfUGMo and AfUGMr differs by 7 Å (Fig. 4.6C), which is clearly resolvable at 
2.75 Å resolution. Furthermore, Arg327 donates a hydrogen bond to the flavin N5 in 
AfUGMo-NADPH (Fig. 4.6B). This hydrogen bond is diagnostic of the oxidized enzyme 
because Arg is an obligate hydrogen bond donor and N5 is an obligate acceptor only in 
the oxidized state. In summary, the flavin is oxidized in the structures determined from 
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the short soaks in NAD(P)H, implying that the trapped species represents the oxidized 
enzyme complexed with the reduced coenzyme. 
 
    
Fig. 4.6 Structural features used to assign the flavin redox state (stereographic views).  In panels A and B, 
the cage represents a simulated annealing σA-weighted Fo - Fc omit map (3.0 σ).  Prior to calculating the 
maps, the flavin, His loop, Trp315, Arg327, and Tyr419 were omitted and simulated annealing refinement 
was performed.  (A) Superposition of NADPH-reduced AfUGM (gray) and dithionite-reduced AfUGM 
(orange, PDB code 3utf). The hydrogen bond between Gly62 and the flavin N5 atom is diagnostic of the 
reduced state.{Dhatwalia, 2012 #3200;Dhatwalia, 2012 #78} (B) AfUGMo-NADPH.  The Arg327-N5 
hydrogen bond and the location of His63 near Trp315 are indicative of the oxidized enzyme.{Dhatwalia, 
2012 #3200;Dhatwalia, 2012 #78} (C) Superposition of AfUGMr (gray) and AfUGMo-NADPH (yellow). 
Black and yellow dashes indicate hydrogen bonds in AfUGMr and AfUGMo-NADPH, respectively. 
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4.3.4 Mutagenesis Studies 
 
 Site-directed mutagenesis (to Ala) was used to assess the importance of selected 
residues in the NAD(P)H binding site (Table 4.2). Three mutations have pronounced 
effects on the kinetics of reduction (R447A, R91A, and S93A). Mutation of Arg447, 
which interacts with the nicotinamide carboxamide, lowers the catalytic efficiency by a 
factor of 2000. This result is consistent with Arg447 helping to guide the nicotinamide 
into position for hydride transfer. Arg91 and Ser93 are on the 90s loop, which forms the 
base of the adenine binding pocket. The R91A and S93A mutations decrease efficiency 
125-fold and 14-fold, respectively. These results are consistent with the 90s loop helping 
to anchor the adenosine moiety. Mutation of Tyr104 or Tyr317, which interact with the 
adenine base, decreases the catalytic efficiency 3-fold. This result is consistent with these 
residues playing ancillary roles in binding the adenine. In summary, Arg447 and the 90s 
loop, which are located at opposite ends of the NADPH binding site, appear to be 
essential for efficient activation of AfUGM by NADPH. 
 
4.4 Discussion 
 
 The structures reported here provide the first images of a UGM complexed with 
NAD(P)H. All of the residues within 3.9 Å of NADPH are identically conserved in other 
eukaryotic UGMs, including TcUGM and Leishmania major UGM, two enzymes that are 
of interest for the design of drugs to treat Chagas disease and leishmaniasis, respectively 
(Fig. 4.7). This level of sequence conservation suggests that the identified binding site is 
physiologically relevant and present in other eukaryotic UGMs. Site-directed 
mutagenesis provides additional validation of the site; mutation of residues contacting 
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NADPH decreases the catalytic efficiency of FAD reduction by factors of 3–2000 (Table 
3.2). 
 The NAD(P)H site of AfUGM is probably different from that of bacterial UGMs. 
Notably, none of the residues that contact the AMP half of the dinucleotide are present in 
the sequences of bacterial UGMs. Furthermore, overlaying NADPH from our structure 
onto K. pneumoniae UGM reveals severe steric clashes with an active site loop (Fig. 4.8). 
The absence of the high affinity NADPH site described here for AfUGM may explain the 
low activity of bacterial UGMs13 with NADPH. For example, we have 
estimated kred for Mycobacterium tuberculosis UGM to be only 0.00002 s–1 
(Supplementary Figure S5), which is several orders of magnitude slower than AfUGM 
and TcUGM. 
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Fig. 4.7 Sequence alignment of the UGMs from Trypanosoma cruzi, Leishmania major, and Aspergillus 
fumigatus.  The secondary structure elements above and below the alignment were derived from the 
structures of T. cruzi UGM and AfUGM, respectively.  This figure was created with CLUSTALW2 
{Chenna, 2003 #3146} and ESPript {Gouet, 2003 #3144}. 
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Fig. 4.8 Superposition of the AfUGMo-NADPH complex and oxidized KpUGM (PDB 2BI7).  AfUGMo is 
shown with domains 1, 2, and 3 colored blue, yellow, and green as in Figure 2A, NADPH is colored pink, 
and FAD is colored yellow.  KpUGM is colored white.  Selected side chains of the 180s loop of KpUGM 
are shown.  Note that these residues occupy the space corresponding to the AMP group of NADPH, which 
suggests that the NADPH binding sites of KpUGM and AfUGM are different.  
 
Finally, the AfUGMo-NADPH structure provides new opportunities for inhibitor 
design. One possible strategy is to target the NADPH site of AfUGMo in order to lock the 
enzyme in the inactive state. Alternatively, the active, reduced enzyme could be targeted 
because the ADP site is also present in AfUGMr (Fig. 4.4B). Retention of the ADP site in 
the reduced enzyme reflects the fact that several residues that contact the ADP moiety 
have similar conformations in AfUGMo and AfUGMr, including Ph66, His68, Arg91, 
Ser93, Tyr104, Tyr317, Asn457, and His460. Both strategies are attractive because one 
could repurpose existing adenosine analogues. Lastly, although the binding of NADPH 
and UDP-Galp is mutually exclusive, the adenine and uracil pockets are distinct and 
separated by 6 Å (Fig. 4.4). Thus, it may be possible to design novel bidentate 
compounds that simultaneously access both pockets. 
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Chapter 5 
 
Structure determination and small angle X-ray studies of 
Leishmania major UDP-Galactopyranose mutase 
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5.1 Introduction 
Recent advances in targeting neglected tropical diseases have led to the 
identification of several enzymes involved in the pathogenesis and virulence of protozoan 
parasite Leishmania major1. Among these enzymes is UDP-galactopyranose mutase 
(UGM) that catalyzes the reversible reaction between UDP-galactopyranose (UDP-Galp) 
and UDP-galactofuranose (UDP-Galf) (Fig. 5.1). L. major is the known cause of 
leishmaniasis (subcutaneous or visceral) affecting mainly inhabitants of tropical and 
subtropical regions. It is estimated that more than 2 million people are affected 
worldwide with leishmaniasis resulting in ~50,000 deaths annually1b. Current treatments 
of leishmaniasis are either highly toxic or expensive1a. 
 
 
  Fig. 5.1 Reaction catalyzed by UGM. 
 
The cell wall of L. major is composed of lipophosphoglycans (LPG) and 
glycoinositolphospholipids (GIPLs) that play a crucial role in the survival of the parasite 
inside human host2. Galactofuranose (Galf) forms a major component of these cell wall 
and extracellular structures. Deletion of the gene encoding UGM (glf) in a mouse model 
shows a delayed onset of lesions at the site of infection thus, UGM is essential for the 
virulence of L. major2. 
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Leishmania major UDP-galactopyranose mutase (LmUGM) shares ~40% 
sequence homology with Aspergillus fumigatus UGM (AfUGM) and ~60% with 
Trypanosoma cruzi UGM (TcUGM). Earlier structures from AfUGM and TcUGM have 
shown that the active sites of these two eukaryotic UGMs are identical3. The 
determination of the structure of LmUGM would help us identify the similarity in the 
active sites of eukaryotic UGMs and thus, developing a common strategy for the 
inhibition of these enzymes. 
 
5.2 Materials and Methods   
 
5.2.1 Crystallization trials 
 
Several crystallization trials were carried out for LmUGM. Prior to setting 
crystallization trays, protein was incubated with 0.5 mM THP. Equal amounts of protein 
(at 8 mg/ml in 25 mM HEPES, 125 mM NaCl pH 7.5) and precipitant were used for 
crystallization trials with and without ligand UDP and substrate UDP-Galp. Plate-shaped 
crystals were obtained within 3-4 days in 19% PEG 3350, 0.2 M ammonium acetate, 0.1 
M Bis-Tris pH 6.5. The crystals of the reduced enzyme were obtained after soaking these 
crystals with 80 mM dithionite and 50 mM UDP. The crystals diffracted to 2.4 Å 
resolution at APS 24-ID-C beamline but had severe pathology such that the density of 
cofactor FAD could not be traced. 
Attempts were made to improve the existing crystal form and obtain new crystal 
forms using techniques such as reductive methylation, limited proteolysis and buffer 
optimization. Also, several crystallization trials were carried out for homologous UGMs 
from Leishmania mexicana and Leishmania infantum. 
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Table 5.1 X-ray diffraction, data collection and refinement statisticsa.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
aValues for the outer resolution shell of 
 data are given in parenthesis.  
bA common set of test reflections (5 %) was used for refinement of all structures. 
cCompared to the parameters of Engh and Huber8. 
 dThe Ramachandran plot was generated with RAMPAGE9. 
 
5.2.2 X-ray diffraction, data collection and refinement 
Several crystals were screened to obtain a good crystal form without any 
pathology. The crystals of LmUGM-UDP complex in reduced state diffracted up to 2.4 Å 
resolution at the APS 24-ID-C beamline (Table 5.1). The structure was solved with 
Enzyme Native 
Active site ligand UDP 
Space group P3121 
Unit cell lengths (Å) a= 82.20, c= 129.23 
Wavelength 1.12711 
Resolution (Å) 19.74 – 2.41   (2.54 – 2.41) 
No. of observations 71316 
No. of unique reflections 20017 
Rmerge(I) 0.048 (0.283) 
Rmeas 0.065 (0.380) 
Rpim 0.042 (0.252) 
Average I/σ 17.0 (3.9) 
Completeness (%) 99.3 (99.4) 
Redundancy 3.6 (3.6) 
Rcryst  0.295 
Rfreeb 0.344 
No. of protein residues                            419 
No. of protein atoms  3129 
Average B-factor (Å2)  
    Protein 55.65 
      FDA 43.07 
      UDP 52.32 
rmsdc  
    Bond lengths (Å) 0.003 
    Bond angles (deg) 0.783 
Ramachandran plotd  
    Favored (%) 93.8% 
    Allowed (%) 5.7% 
    Outliers (%) 0.5% 
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MOLREP4 using a chainsaw model of TcUGM-UDP reduced as the starting point. Clear 
density for the cofactor FAD and ligand UDP was observed. The structure was manually 
built using COOT5 and then refined using PHENIX6. Unlike other eukaryotic UGMs that 
crystallized with high solvent content of 74%, LmUGM crystallized with one molecule in 
the asymmetric unit with a solvent content of 44.8% and Vm 2.23 Å3/Da, as suggested by 
Matthew’s probability7. 
 
5.2.3 Small-angle X-ray scattering (SAXS) 
 SAXS experiments were performed at beamline 12.3.1 of the Advanced Light Source 
via the mail-in program10. Prior to data collection, the protein sample was subjected to 
size exclusion chromatography using a Superdex 200 column that had been equilibrated 
in 50mM Tris, 500mM NaCl, 1mM THP, 5mM UDP pH 8.0 buffer.  Scattering 
intensities were measured at three nominal protein concentrations (2 - 6 mg/mL).  For 
each protein concentration, exposure times of 0.5, 1.0, 3.0, and 6.0 sec were used. 
Scattering curves collected from the protein samples were corrected for background 
scattering using intensity data collected from the dialysis buffer.  A composite scattering 
curve was generated with PRIMUS11 by scaling and merging the low q region from the 
lowest concentration sample (0.5 sec exposure) with the high q region from the lowest 
concentration sample (0.5 sec exposure).  PRIMUS was also used to perform Guinier 
analysis.  GNOM was used to calculate pair distribution functions.12 FoXS was used to 
calculate theoretical scattering profiles from atomic models.13  MOLEMAN was used to 
calculate Rg from atomic coordinates. The SASTBX server14 was used for shape 
reconstruction calculations.  
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5.3 Results 
 
5.3.1 SAXS results   
The oligomeric state and quaternary structure were determined using SAXS.    
Guinier analysis indicated a radius of gyration (Rg) of 24.8 ± 0.1 Å (Fig. 5.3, inset).  
Calculations of the pair distribution function suggest Rg of 24.4 – 24.8 Å and maximum 
particle dimension of 70 – 80 Å.  For reference, a monomer of TcUGM has Rg of 22.8 Å, 
which suggests that LmUGM is monomeric.  Indeed, the SAXS curve calculated from a 
TcUGM monomer exhibits good agreement with the experimental curve (Fig. 5.3), and 
the SAXS shape reconstruction is consistent with the size and shape of the TcUGM 
monomer (Fig. 5.3).  It is concluded that LmUGM is monomeric in solution and has the 
same fold as TcUGM.      
 
 
 
 
 
Fig. 5.2 SAXS analysis of LmUGM.  (A) Experimental and calculated SAXS curves. The inset shows a 
Guinier plot spanning the range of qRg of 0.309 – 1.29.  The best fit line has R2 of 0.9977).  (B) 
Superposition of the SAXS shape reconstruction and a monomer of TcUGM.  The correlation coefficient 
between the envelope and the model is 0.94.  
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5.3.2 Structure of LmUGM complexed with UDP 
 The structure of LmUGM was solved at 2.4 Å in complex with UDP in the 
reduced state. LmUGM shares a common fold as other eukaryotic UGMs and is the 
second structure from a pathogenic protozoan. The binding of inhibitor UDP in the active 
site of enzyme is identical to that in AfUGM and TcUGM as shown by superposition of 
the three eukaryotic UGM structures (Fig. 5.4). Thus, LmUGM makes similar 
interactions with UDP as observed earlier3 (Fig. 5.4). The 170s flap is in the closed 
conformation but the residues starting from 180 to 202, including the 200s flap are 
disordered in the structure. The conformation of histidine loop is the same as observed 
earlier for eukaryotic UGMs in the reduced state (PDB code: 3UTF3a and 4DSH3b). The 
conserved His59 is present on the si side of flavin isoalloxazine and the carbonyl oxygen 
of Gly58 forms a hydrogen bond with N5 of flavin (FADH−). 
 
    
 
Fig. 5.3 Superposition of the active sites of LmUGM (green), TcUGM (magenta) and AfUGM (cyan). UDP 
is bound in the active and all the residues involved in interactions are shown as sticks. 
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6.1 Introduction 
 
 
Histidine acid phosphatases (HAPs) are enzymes that are optimally active at acidic 
pH and utilize an active site histidine residue for catalysis. A general scheme of the 
reaction catalyzed by HAPs is shown below (Fig. 6.1). 
 
 
   Fig. 6.1 An enzyme- catalyzed reaction with a phosphomonoester substrate. 
 
The active site histidine acts as a nucleophile and is phosphorylated during the 
reaction (Fig. 6.2). The alkoxide group (RO-) is then transferred to a nearby proton donor 
forming a phosphoenzyme intermediate with the further transfer of phosphoryl group to 
water at acidic pH.  
 
   Fig. 6.2 Catalytic mechanism of the histidine phosphatase superfamily1. 
 
HAPs are present in bacteria as well as humans. An example of HAPs is human 
prostatic acid phosphatase (PAP) that has recently been discovered to be a pain 
suppressor2. Studies show that PAP posseses potent and long-lasting antinociceptive 
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properties and is eight times more potent than the opiod analgesic morphine. Furthermore, 
the antinociceptive properties of PAP have been attributed to its ability to catalyze the 
dephosphorylatation of 5’-AMP to generate adenosine that activates A1-adenosine 
receptors in dorsal spinal cord2. An intrathecal injection of hPAP into the wild-type mice 
showed increased thermal and mechanical sensitivity. The paw-withdrawal latency of 
mice to a thermal stimulus increased up to six hours and remained elevated up to 3 days3. 
 
 
Fig. 6.3 Proteins that regulate extracellular adenosine levels also influence adenosine receptor activation 4.  
 
On the contrary, adenosine itself is also known to have analgesic properties in 
mammals but has several disadvantages to it. First, although it has antinociceptive effects 
in humans, it is not currently used to treat chronic pain in patients because of 
cardiovascular side effects 4. Second, the basal concentration of adenosine ranges from 50-
200 nM and has a short half-life in blood (few seconds) and spinal cerebrospinal fluid (10-
20 min)4. Thus, due to its rapid metabolism it is not a very efficient analgesic.   
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  Interestingly, ectonucleotidases are stable in vivo and have A1R-dependent 
antinociceptive effects that last for 2-3 days and might have sustained analgesic effects in 
patients. Moreover, as enzymes are catalytically restricted, ectonucleotidases would 
generate adenosine in proportion to the substrate (5’-AMP) availability. Thus, it will have 
fewer side effects as compared to adenosine itself, which is effective only when given in 
higher doses. Also, ATP levels are increased post injury providing additional substrate for 
ectonucleotidases to generate adenosine4.   
These studies provoke the question that whether bacterial HAPs also posses 
antinociceptive properties and how bacterial HAPs are different structurally from 
mammalian HAPs. The major focus of this study was to determine the crystal structure of 
HAP from a human pathogen Legionella pneumophila (LpHAP). LpHAP is an 
extracellularly secreted enzyme and shares significant sequence homology with the human 
HAP as compared to other bacterial acid phosphatases5. Sequence conservation shows that 
LpHAP shares ~30 % sequence identity with hPAP and 40% with FtHAP (a previously 
studied bacterial HAP from Francisella tularensis). Thus, LpHAP might serve as a better 
model to study substrate recognition in this class of enzymes. 
 
6.2 Materials and Methods 
6.2.1 Cloning, expression and purification 
The gene for LpHAP was cloned into pET-20b vector using NcoI and XhoI 
restriction sites. Native LpHAP was expressed using a modified autoinduction6 method. 
Briefly, the cells were grown in BL21(AI) at 37°C for ~3h and then after the addition of 
0.2% arabinose, the temperature was reduced to 18°C. The cells were harvested after 28 
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hrs. Protein was purified to homogeneity after two-step purification using Ni-affinity and 
anion-exchange chromatography.  
 
6.2.2 Crystallization of LpHAP 
 Crystallization trials were carried out using vapor diffusion technique in sitting 
drop crystal trays. Crystals were grown using protein at ~8.0 mg/ml in the buffer 50 mM 
Tris, 50 mM NaCl, 1 mM EDTA pH 7.5. Equal amounts of protein and reservoir solution 
were mixed and plate-shaped crystals of the native enzyme were obtained in 10% PEG 
8000, 0.1 M imidazole pH 8.0, 0.2 M calcium acetate (Fig. 6.4A) These crystals diffracted 
to a low resolution of 3.5 Å. To improve the resolution, crystals were then grown in 
complex with L(+)-tartrate, which is a known competitive inhibitor for this class of 
enzymes7. Tetragonal-shaped crystals were obtained in 20% PEG 3350 and 0.2 M sodium 
acetate at pH 4.5 (Fig. 6.4B). 
   
             Fig. 6.4 Crystals of (A) LpHAP and (B) LpHAP with L-tartrate. 
 
6.2.3 X-ray Diffraction, Data Collection and Refinement 
The crystals of LpHAP were analyzed at APS beamline 24-ID-C using Quantum 
315 detector, where they diffracted up to a resolution of 2 Å. A data set of 360 images was 
collected by a 0.5° rotation of the crystal and the data was processed using d*TREK and 
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scaled using SCALA8 via CCP4i9. The structure of LpHAP was solved by molecular 
replacement using MOLREP10 with FtHAP as the starting model, which shares 40 % 
sequence identity with LpHAP. The initial solution from MOLREP was then subjected to 
model building using Phenix.Autobuild11. The structure was built using COOT12 and 
refined using several iterations of PHENIX13. Data collection and refinement statistics are 
listed in Table 6.1. 
 
Table 6.1 X-ray diffraction, data collection and refinement statisticsa. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
aValues for the outer resolution shell of data are given in parenthesis.  
bA common set of test reflections (5 %) was used for refinement of all structures. 
cCompared to the parameters of Engh and Huber14. 
 dThe Ramachandran plot was generated with RAMPAGE15. 
Enzyme Native 
Active site ligand L(+)-tartrate 
Space group C2 
Unit cell lengths (Å) a= 217.88, b=134.27, c= 135.780 
β = 127.46 
Wavelength 1.12711 
Resolution (Å) 50.00 – 2.00    (2.07 – 2.00) 
No. of observations 745974 
No. of unique reflections 207120 
Rmerge(I) 0.079 (0.451) 
Average I/σ 20.3 (2.7) 
Completeness (%) 99.6 (98.6) 
Redundancy 3.6 (3.3) 
Rcryst  0.204 
Rfreeb 0.241 
No. of protein residues 657 
No. of protein atoms  5129 
No. of water molecules 413 
Average B-factor (Å2)  
    Protein 31.05 
    Water 27.82 
    Active site ligand 38.00 
rmsdc  
    Bond lengths (Å) 0.007 
    Bond angles (deg) 0.975 
Ramachandran plotd  
    Favored (%) 98.3% 
    Allowed (%) 1.6% 
    Outliers (%) 0.1% 
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6.2.4 Kinetic characterization of LpHAP 
An initial substrate screening for the enzyme was done using malachite green 
assay16. The reaction was carried out for a period of 15 min and the amount of phosphate 
released was measured spectrophotometrically at 625 nm. The potential substrates 
identified from this screening (3’-AMP and 5’- AMP) were then studied using steady-state 
enzyme kinetics. Enzymatic activity was measured at 37 °C using a discontinuous assay in 
the buffer 0.2 M sodium acetate pH 5.5.  Different substrate concentrations were used and 
the amount of phosphate generated was measured spectrophotometrically at 625 nm. For 
each substrate concentration, the reaction was stopped at four different time points, i.e, 15, 
75, 135, and 195 seconds, using malachite green-ammonium molybdate reagent. 
 The inhibition constant for LpHAP was determined using L(+)-tartrate as 
inhibitor. The enzymatic activity was measured using a discontinuous assay and similar 
buffer conditions were used with L(+)-tartrate. Different concentrations of the substrate p-
nitrophenyl phosphate (pNPP) were used and for each substrate concentration, the 
reaction was stopped at four different time points, i.e, 15, 75, 135, and 195 seconds using 
0.5 M glycine pH 10. Steady-state kinetic constants were determined by measuring the 
amount of p-nitrophenolate (pNP) formed spectrophotometrically at 405 nm. 
 
6.3 Results and Discussion 
6.3.1 Structure of LpHAP complexed with L(+)-tartrate  
The structure of LpHAP was determined in complex with the competitive inhibitor 
L(+)-tartrate. LpHAP shares a similar fold with other members of HAP superfamily. It 
consists of two domains: the core domain that consists of the catalytic residue (His34) and 
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the cap domain that helps in substrate recognition. LpHAP crystallized with eight 
molecules in the asymmetric unit as shown below (Fig.6.5). 
 
            
 
Fig. 6.5 (a) Overall structure of LpHAP with four dimers in the asymmetric unit. (b) LpHAP protomer with 
bound L-tartrate shown as spheres in red. The active site residues His34, Ile40, Arg 158, His280, and Asp 
281 are shown as sticks.   
 
Previous studies have shown that HAPs exist as dimers in solution17. Similar 
interlocking dimer was observed for LpHAP. The protomer structure of LpHAP 
complexed with L(+)-tartrate is shown (Fig. 6.5b). The hydroxyl groups of L(+)-tartrate 
are engaged in hydrogen bonding interaction with His34, Arg33, Asp281 and Arg101 
residues. 
 
6.3.2 A comparison of LpHAP, FtHAP and hPAP 
             The superposition of the protomer structures of LpHAP, FtHAP and hPAP reveal 
a shift in the position of α3 helix (Fig. 6.6). This shift in α3 helix might be responsible for 
different substrate preferences of this class of enzymes. The position of α3 helix in hPAP 
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results in a broader active site consistent with the wide substrate preference of this 
enzyme. hPAP is known to bind large phosphoproteins in addition to nucleoside 
phosphates, whereas, the narrower active site entrance of FtHAP precludes the binding of 
large substrates17. In LpHAP, α3 helix lies in between that of FtHAP and hPAP which 
makes it more closer homologue of hPAP as suggested earlier5. Thus, the substrate 
binding preferences of this enzyme might be closer to hPAP.  
         
Fig. 6.6 Superposition of protomer structures of LpHAP (yellow), FtHAP (red) and hPAP (green) depicting 
a shift in α3 helix.          
              
           Previously determined structure of FtHAP mutant D261A complexed with 3´-AMP 
revealed the presence of an aromatic clamp formed by the active site residues Phe23 and 
Tyr13517. Sequence alignment shows that in LpHAP, the substrate clamping residues 
Phe23 and Tyr135 are substituted by Ile40 and Arg155 respectively. 
Both the residues Tyr135 (in FtHAP) and Arg155 (in LpHAP) are present on α3 
helix that is shifted in LpHAP by 8 Å as compared to FtHAP (Fig. 6.6). In FtHAP, the 
distance between the adenine base of 3’-AMP and substrate clamping residues Phe23 and 
Tyr135 is 3.5 Å and 3.9 Å, respectively, whereas, in LpHAP analogous residues Ile40 and 
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Arg155 are separated by 15 Å. Thus, Arg155 is too far to form an aromatic clamp 
analogous to FtHAP.  
          The shift in α3 helix and the absence of an aromatic clamp in LpHAP suggests that, 
LpHAP might bind nucleoside monophosphate substrates in a different manner as 
compared to that in FtHAP. Also, sequence analysis and structural alignment shows that 
His205 residue is present in the active site of LpHAP, instead of the conserved Asp 
residue in FtHAP and hPAP. A low resolution structure of D281A mutant of LpHAP at 
3.5 Å was determined in complex with 5’-AMP (data not shown) suggesting that His205 
might also play a role in substrate clamping, as analogous Arg155 residue is farther away. 
These results suggest that LpHAP might have a different substrate binding mechanism 
unique among HAPs. 
 
6.3.2 Kinetic characterization of LpHAP   
 Steady-state kinetic parameters were measured for the preferred substrates 3’-
AMP and 5’-AMP (Fig. 6.8). The Km for 3’-AMP is 10-fold greater as compared to that 
of FtHAP. This might be due to the broader active site for LpHAP in contrast to FtHAP. 
The kcat iss ~100-fold less than FtHAP thus, resulting in ~380 fold lower catalytic 
efficiency as compared to FtHAP (Table 6.2). 
 
Table 6.2 Steady-state kinetic parameters of LpHAP. 
Enzyme Substrate Km  (mM) kcat  (s-1) kcat/Km  (s-1 mM-1) 
 
LpHAP 
 
3´-AMP 
    3.3±0.6 3.0 ± 0.3 0.932 
 
LpHAP 
 
5´-AMP 
3.8±0.5 2.40 ± 0.15 0.631 
 
FtHAP 
 
3´-AMP 
0.315±0.001 119.9 ± 0.1 381 
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Fig. 6.7 Michaelis-Menten plots of LpHAP using substrates 3’-AMP and 5’-AMP. 
           
 The inhibition constant for LpHAP was determined using pNPP as substrate and 
L(+)-tartrate, which is a known competitive inhibitor for HAPs. The inhibition constants 
for hPAP and FtHAP were determined previously are 0.15 mM and 0.2 mM 
respectively17-18. The Ki for LpHAP is 0.43 μM that is ~50 times lower than the 
corresponding values for hPAP and FtHAP. Thus, L(+)-tartrate is a better inhibitor for 
LpHAP as compared to hPAP and FtHAP. 
   
                              Fig. 6.8 Inhibition of LpHAP using L(+)-tartrate as inhibitor 
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A.1 Crystallization and structural analysis of active
 site mutant G61P of Trypanosoma cruzi UDP-Galactopyranose mutase 
(TcUGM) 
 
Large conformational changes have been observed in UGMs, both prokaryotic and 
eukaryotic, upon substrate binding1. In contrast, the catalytic histidine loop undergoes 
conformational changes upon FAD reduction that are unique to eukaryotic UGMs1a, b. 
These changes are substantial in AfUGM upon reduction with dithionite, where catalytic 
His63 moves from the re side of flavin to the si face of flavin and stacks parallel to the 
middle ring of isoalloxazine1a. In TcUGM, the histidine loop is retracted in oxidized state 
but upon FAD reduction, shifts by a distance of 2.3 Å towards isoalloxazine ring1b. 
Interestingly, no such conformational change associated with the histidine loop has been 
observed before in any of the prokaryotic UGMs. 
The histidine loop plays an important role in the catalytic activity of UGMs1b.  The 
backbone carbonyl oxygen of second glycine of GGH loop forms a hydrogen bond with 
N5 of reduced FAD (FADH-). In bacterial UGMs, this residue is replaced by either Pro or 
Ala that are known for inducing rigidity in protein secondary structures. Steady-state 
enzyme kinetics shows that mutation of Gly61 residue in TcUGM to either Ala or Pro 
(analogous to bacterial UGMs) is highly detrimental to its catalytic activity2. These 
results suggest that glycine residue might impart flexibility to histidine loop required for 
efficient catalysis in eukaryotic UGMs1b.  
To understand the structural basis of histidine loop flexibility, the structures of 
TcUGM G61P mutant complexed with UDP were determined in the oxidized and 
reduced states.  
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A.1.1. Crystallization  
The TcUGM histidine loop mutant G61P was crystallized at 7–8 mg/mL in the 
buffer 50 mM HEPES, 150 mM NaCl at pH 7.5. Prior to crystallization, the enzyme was 
incubated with 10 mM UDP for 30 min. Crystallization experiments were performed at 
20 °C using sitting drop vapor diffusion with the drops formed by mixing 1.5 μL each of 
the protein and reservoir solutions. Crystals were grown in the same condition as native 
enzyme with reservoirs containing ammonium sulfate and HEPES buffer1b. Small yellow 
block-shaped crystals appeared after 4-6 weeks. The optimized crystallization reservoir 
consisted of 1.2 M ammonium sulfate and 0.1 M HEPES at pH 7.5. The crystals were 
cryoprotected in 1.4 M ammonium sulfate, 0.1 M HEPES pH 7.5, and 25% ethylene 
glycol before plunging into liquid N2. The space group is P3221 with unit cell dimensions 
of a = 143 Å and c = 166 Å and two molecules in the asymmetric unit.  
 Crystals of G61P-UDP complex with FAD in the reduced state were prepared by 
soaking the aforementioned crystals in 1.4 M ammonium sulfate, 0.1 M HEPES pH 7.5, 
60 mM sodium dithionite, and 25% ethylene glycol. Once the crystals turned from yellow 
to colorless, they were flash-cooled by plunging into liquid N2. 
 
A.1.2 X-ray diffraction, data collection, phasing and refinement 
 The diffraction data for oxidized and reduced G61P–UDP were collected at 
beamline 24-ID-C. The data were integrated using XDS3 and scaled with SCALA4 via 
CCP4i5. Data processing statistics are listed in Table A.1.1. 
 The phase problem for oxidized G61P–UDP was solved using molecular 
replacement as implemented in MOLREP6. The search model was derived from the 
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structure of oxidized TcUGM (PDB code 4DSG1). Molecular replacement calculations 
produced a solution having two molecules in the asymmetric unit with R-factor of 0.45 
and score of 0.60. The structure was built using COOT7 and refined using PHENIX8. 
Data refinement statistics are listed in Table A.1.1.  
 
Table A.1.1 X-ray Diffraction Data Collection and Refinementa 
     
 G61P-Oxidized G61P-Reduced 
Space group P3221 P3221 
Unit cell parameters (Å) a = 142.9,  
c = 166.2 
a = 143.3,  
c = 168.0 
Wavelength (Å) 0.9791 0.9795 
Resolution (Å) 166.23 - 2.77 
(2.92 - 2.77) 
124.15 - 2.92 
(3.08 - 2.92) 
Observations 309683 241052 
Unique reflections 50464 43797 
Rmerge(I)b 0.091 (0.778) 0.110 (0.750) 
Rmeas(I)b 0.099 (0.848) 0.122 (0.830) 
Rpim(I)b 0.040 (0.331) 0.051 (0.351) 
Mean I/σ 17.0 (2.5) 13.8 (2.4) 
Completeness (%) 99.7 (99.4) 99.8 (99.4) 
Multiplicity 6.1 (6.1) 5.5 (5.6) 
No. of protein residues 944 915 
No. of protein atoms 7592 7223 
No. of FAD atoms 106 106 
No. of ligand atoms 50 50 
No. of water molecules 1 0 
Rcryst  0.190 0.202 
Rfreec 0.225 0.254 
rmsd bond lengths (Å)d 0.009 0.008 
rmsd bond angles (°)d 1.21 1.19 
Ramachandran plote   
  Favored (%) 95.9 95.0 
  Allowed (%) 4.4 4.6 
  Outliers (%) 0.4 0.3 
Average B-factor (Å2)   
  Protein 65 70 
  FAD 59 66 
  UDP 54 59 
  Water 49 0 
Coordinate error (Å)f 0.44 0.53 
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aValues for the outer resolution shell of data are given in parenthesis.  
bDefinitions of Rmerge, Rmeas, and Rpim can be found in Weiss 9. 
cA common set of test reflections (5 %) was used for refinement of both structures. 
dCompared to the parameters of Engh and Huber 10. 
eThe Ramachandran plot was generated with RAMPAGE 11. 
fMaximum likelihood-based coordinate error estimate from PHENIX8. 
 
 
A.1.3 Results and Discussion 
 
The structures of TcUGM mutant G61P were solved in complex with UDP in 
oxidized and reduced states. In oxidized state, the two structures differ in the 
conformation of histidine loop (Fig. A.1.1(a)). In TcUGMox, the histidine loop is retracted 
from FAD isoalloxazine and the backbone carbonyl of Gly61 is 5 Å away from N5 of 
FAD. In contrast, when proline substitutes Gly61 in G61P structure, the loop shifts by 1.7 
Å towards isoalloxazine to form a hydrogen bond between backbone carbonyl of Pro61 
and N5 of isoalloxazine. Upon reduction with dithionite, the two structures are identical 
with similar hydrogen bonding distance of 2.9 Å (Fig. A.1.1(b)).        
 
                   
 
Fig. A.1.1 (a) Superposition of TcUGM (yellow) and G61P mutant (green) in the oxidized state (b) 
Superposition of TcUGM (cyan) and G61P mutant (magenta) in the reduced state.  
   122 
The superposition of the oxidized and reduced structures of Klebsiella 
pneumoniae UGM (KpUGM) shows the two structures are exactly identical (Fig. A.1.2). 
The only difference lies in the planarity of FAD isoalloxazine ring; being planar in the 
oxidized state and butterfly-shaped bent in the reduced state. The backbone carbonyl 
oxygen makes a hydrogen bond with FAD isoalloxazine N5 in both oxidized and reduced 
states. This hydrogen- bonding pattern is similar to that observed in G61P structure, 
where Gly61 is substituted by Pro, analogous to bacterial UGMs. 
 
   
 
Fig. A.1.2 Superposition of Klebsiella pneumoniae UGM (KpUGM) in the oxidized (yellow) and reduced 
(magenta) states.  
 
Thus, proline induces rigidity in the histidine loop such that, even in oxidized 
state enzyme is locked in the same conformation as in reduced state. In eukaryotic 
UGMs, the presence of Gly instead of Pro/Ala imparts flexibility to the histidine loop 
such that in oxidized state, the loop is farther away from FAD isoalloxazine, whereas, in 
reduced state it forms a hydrogen bond to stabilize the active form of enzyme.  
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A.2 Structure determination of UDP-galactopyranose mutase in 
complex with substrate analogs UDP-arabinopyranose and UDP-
arabinofuranose 
 
Several enzymes in the Galactofuranose (Galf) biosynthetic pathway have been 
characterized but not much is known about the metabolism of arabinofuranose (Araf). 
The only structural difference between the two monosaccharides is that L-arabinose has a 
shorter side chain at C4 as compared to D-galactose. 
Previous studies have shown that UDP-L-Arabinopyranose (UDP-Arap) can 
undergo interconversion to UDP-L-Arabinofuranose (UDP-Araf) in the presence of 
Escherichia coli UDP-Galactopyranose mutase (EcUGM)1. However, the surface 
glycoconjugate structures of bacteria, fungi and protozoans have D-arabinofuranose, 
whose precursor is β-D-arabinofuranosyl-1-monophosphoryldecaprenol2. Interestingly, 
L-arabinofuranose forms a major component of plant cell wall structures3. Recently, a 
plant mutase UDP-Arabinopyranose mutase (UAM) was identified that catalyzes the 
conversion of UDP-Arap into UDP-Araf3. These enzymes belong to the reversibly 
glycosylated polypeptides (RGP) family and are different as compared to UGMs as they 
do not require any cofactor and thus, are not FAD-dependent3. 
Structural characterization of AfUGM in complex with substrate analogs UDP-
Arap and UDP-Araf would help us determine how UGM recognizes specifically UDP-
galactopyranose and not UDP-arabinopyranose. 
 
A.2.1 Soaking AfUGM with substrate analogs UDP-Arap and UDP-Araf 
 
Crystals of AfUGM K344A/K345A were grown in the condition consisting of 1.2 
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M ammonium sulfate and 0.1 M sodium acetate pH 4.5 as discussed previously 4. Yellow 
hexagonal crystals were obtained in 3-4 days. The crystals were soaked simultaneously 
with 80 mM dithionite and 70 mM UDP-L-arabinopyranose for 9 min in the 
cryoprotectant consisting of 1.6 M ammonium sulfate, 0.1 M sodium acetate pH 4.5 and 
25 % ethylene glycol.  
Similar strategy was used for the soaking of AfUGM crystals with UDP-L-
arabinofuranose. The crystals were soaked with 80 mM dithionite and 6.2 mM UDP-L-
arabinofuranose for 4 min in the cryoprotectant consisting of 1.6 M ammonium sulfate, 
0.1 M sodium acetate pH 4.5 and 25 % ethylene glycol. 
 
A.2.2 X-ray diffraction, data collection and refinement 
 The data for AfUGM complexed with UDP-Arap and UDP-Araf in the reduced 
state was collected at ALS beamline 4.2.2 using CMOS detector. The data sets were 
integrated using XDS5, scaled with SCALA6  via CCP4i7. Data collection and refinement 
statistics are listed in Table A.2.1. 
 
Table A.2.1 X-ray Diffraction Data Collection and Refinementa     
 UDP-Arap UDP-Araf 
Space group P6522 P6522 
Unit cell parameters (Å) a = 217.8,  
c = 318.0 
a = 218.1,  
c = 320.5 
Wavelength (Å) 0.9791 0.9795 
Resolution (Å) 64.21 - 2.95 (2.95 
- 2.80) 
62.97 – 3.06 (3.06 
– 2.90) 
Observations 1218850 1108518 
Unique reflections 108989 88525 
Rmerge(I)b 0.306 (1.134) 0.445 (1.272) 
Rmeas(I)b 0.336 (1.247) 0.481 (1.379) 
Rpim(I)b 0.139 (0.517) 0.178 (0.520) 
Mean I/σ 8.2 (2.0) 5.8 (1.8) 
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Completeness (%) 99.7 (98.3) 89.7 (90.3) 
Multiplicity 11.2 (11.2) 12.5 (12.3) 
No. of protein residues 2019 2019 
No. of protein atoms 15499 15698 
No. of FAD atoms 212 212 
No. of ligand atoms 68 68 
No. of water molecules 19 4 
Rcryst  0.204 0.207 
Rfreec 0.244 0.257 
rmsd bond lengths (Å)d 0.008 0.008 
rmsd bond angles (°)d 1.15 1.21 
Ramachandran plote   
  Favored (%) 95.9 95.0 
  Allowed (%) 4.4 4.6 
  Outliers (%) 0.4 0.3 
Average B-factor (Å2)   
  Protein 41 39 
  FAD 58 46 
  UAD 72 54 
  Water 30 27 
Coordinate error (Å)f 0.38 0.40 
 
 
aValues for the outer resolution shell of data are given in parenthesis.  
bDefinitions of Rmerge, Rmeas, and Rpim can be found in Weiss 8. 
cA common set of test reflections (5 %) was used for refinement of both structures. 
dCompared to the parameters of Engh and Huber 9. 
eThe Ramachandran plot was generated with RAMPAGE 10. 
fMaximum likelihood-based coordinate error estimate from PHENIX 
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A.3 Crystallization of flavin domain of tetrahydrofuran monooxygenase 
(ThmD-FD) 
 
 
Tetrahydrofuran monooxygenase (Thm) is a member of bacterial multicomponent 
monooxygenases (BMM). The enzyme catalyzes hydroxylation of tetrahydrofuran to 2-
hydroxytetrahydrofuran in the presence of NADH and O2. Thm is composed of three 
subunits: a hydroxylase subunit with [2Fe-2S], a regulatory subunit, and an 
oxidoreductase component named ThmD.  These enzymes have potential application in 
bioremediation as they are capable of cleaving C-H bond in hydrocarbons and catalyze 
the hydroxylation of their substrates1.  
 
        
                  Fig. A.3.1 Catalytic cycle of tetrahydrofuran monooxygenase (Thm)2. 
 
ThmD from Pesudonocardia sp. strain K1 capable of growing on tetrahydrofuran 
as the sole carbon source, was earlier characterized and purified to homogeneity2. ThmD 
has a molecular weight of 39,845 Da (~40 kDa) and exists as a monomer in solution. 
 Previous studies on methane monooxygenase (MMO) have shown that both FAD 
binding domain and [2Fe-2S] domain are capable of folding independently from each 
other but still are functional3. Interestingly, the oxidoreductase component of ThmD is 
different than other members of the BMM family in that it has a covalently attached 
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FAD2. The typical sites for attachment to FAD are at C6 and C8α- methyl group of the 
isoalloxazine ring. Mutations and computational studies to determine the site of covalent 
attachment in ThmD did not reveal any characteristic residues such as His, Cys or Tyr to 
be involved. Thus, a new site for covalent attachment or a novel fold has been proposed 
for this enzyme2. These findings motivated us to determine the three-dimensional 
structure of ThmD.  
 
A.3.1 Crystallization of ThmD-FD 
 
Extensive crystallization trials were carried out to crystallize the FAD binding 
domain of ThmD (ThmD-FD). No crystals were obtained using the commonly available 
crystallization screens. Thus, the protein was modified using iodoacetic acid4. The 
protein was dialyzed overnight into the buffer 25 mM Tris, 100 mM ammonium sulfate, 
0.5% iodoacetatic acid pH 7.8. Commercially available screens were used to set up initial 
crystallization trials. Few conditions (PEG3350 as the precipitant) yielded dark yellow 
crystals those were previously never discovered. Few rounds of optimization produced 
long rods. The final optimized condition consisted of 27% PEG 3350, 0.2 M MgCl2, 0.1 
M Tris pH 8.5. Crystals of SeMet derivative were obtained in the same condition. Partial 
structure was solved but the density of FAD was not completely traceable. 
 
A.3.2 X-ray diffraction, data collection and structure refinement 
 
Several single-wavelength anomalous diffraction data sets were collected at the 
wavelength corresponding to the experimentally measured peak of f″. The phasing 
potential of each data set was assessed with the HKL2MAP interface5 to the 
SHELXC/D/E programs5-6. Strong heavy atom signal was not observed which might be 
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due to only 60% incorporation of Se, as shown by mass spectrometry results (data not 
shown). Finally, a data set with 2.43 Å resolution and good anomalous signal was 
identified. Overall, 12 heavy atom sites were identified with occupancy greater than 0.5. 
As only five methionine residues were present in the sequence, other heavy atom sites 
might be due to iodine incorporation by enzyme modification with iodoacetic acid. These 
heavy atom sites were then input to PHENIX AutoSol7 for single-wavelength anomalous 
diffraction phasing, density modification, and automated building.  
Partial structure of ThmD-FD was solved but the electron density for FAD 
cofactor remained elusive. The model from automated building was built and extended 
manually in COOT8. Data collection and refinement statistics are listed in Table A.3.1.  
 
Table A.3.1 X-ray diffraction, data collection and refinement statisticsa. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
aValues for the outer resolution shell of data are given in parenthesis.  
bDefinitions of Rmerge, Rmeas, and Rpim can be found in Weiss9. 
cCompared to the parameters of Engh and Huber10. 
Parameters SeMet –ThmD 
Space group P43 
Unit cell lengths (Å) a= 61.0, c= 71.70 
Wavelength 0.97918 
Resolution (Å) 46.47 – 2.43   (2.56 – 2.43) 
Rmerge(I) 0.124 (0.925) 
Rmeas 0.128 (0.958) 
Rpim 0.034 (0.248) 
Average I/σ 14.9 (3.2) 
Completeness (%) 99.9 (99.9) 
Multiplicity 14.7 (14.9) 
Mid-slope of anomalous 
normal probability 
1.159 
No. of observations 146836 
No. of unique reflections 10009 
Rcryst                           0.372 
Rfree 0.417 
rmsd bond lengths (Å)c 0.009 
rmsd bond angles (°)c 1.483 
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A.4 Expression, purification and crystallization of 2-Haloacrylate 
hydratase (2-HAH) 
 
 2-Haloacrylate hydratase is a flavoenzyme that catalyzes the conversion of 2-
chloroacrylate (2-CAA) to pyruvate (Fig. A.4.1)1. The enzyme has an absolute 
requirement for reduced FAD (FADH2) and reducing partner NAD(P)H for efficient 
catalysis1-2. Due to the interesting chemistry and possible applicability of 2-HAH in the 
chemical industry, we collaborated with the Sobrado laboratory to unravel the structure 
and, thereby, function of this novel flavoenzyme. Moreover, the enzyme is similar to 
UDP-galactopyranose mutase (UGM) as it requires reduced FAD for activity, but 
catalyzes the reaction without any net transfer of electrons.  
       
   Fig. A.4.1 Reaction catalyzed by 2-haloacrylate hydratase1. 
 
A.4.1 Cloning, expression and purification of 2-HAH 
 2-HAH (547 amino acid) from Pseudomonas sp. YL (2-HAHYL) was cloned into 
pVP56K vector by Sobrado laboratory. Briefly, the cloning of 2-HAHYL into pVP56K 
vector results in a construct with N- terminal 8xHis-maltose-binding-protein(MBP)-
TEVP cleavage site 2-HAHYL with kanamycin resistance.  
 The construct thus obtained was transformed into BL21(DE3)pLysS and the 
resulting transformant was used for further experiments. 2-HAHYL was expressed using 
autoinduction in terrific broth (TB) media. Briefly, overnight culture was prepared by 
inoculating a 50 mL LB broth media supplemented with kanamycin at 40 μg/mL. The TB 
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culture supplemented with 100 mL phosphate buffer, 2.4 mL of 1 M MgSO4, 30 mL 15% 
(wt) succinic acid (pH 4.5), 40 mL of 30x80155 (prepared by dissolving 240 mL of 
glycerol, 4.5 g of glucose, 150 g of lactose per liter in water and sterile filtered) and 
40μg/mL kanamycin was inoculated using 1% starter culture. The culture was incubated 
at 37 °C and 250 rpm for ~ 6 hrs (O.D. 600 ~ 3.0) and then temperature was lowered to 
18 °C and cultures were incubated overnight.  Following day, the cells were harvested by 
centrifuging at 3500 rpm at 4 °C for 30 min. The resulting cells were resuspended in 20 
mM Tris, 300 mM NaCl, 10% glycerol pH 7.5 (Buffer A) and flash frozen at -80 °C until 
further purification. 
 Cells were thawed and ruptured by sonication and centrifuged at 17,000 rpm at 4 
°C for 45 min to remove the cell debris. After 45 min, the supernatant was transferred 
into fresh tubes and centrifuged again at 17,000 rpm for another 30 min. The supernatant 
thus obtained was loaded onto Ni2+ column and the protein was purified using 
conventional Ni-IDA method in which the 2-HAHYL was eluted using a step gradient of 
20 mM Tris, 300 mM NaCl, 10 % glycerol, 1 M imidazole pH 7.5 (buffer B). Bright 
yellow samples were pooled together and were divided into two different fractions. For 
crystallization purposes, we used MBP-2-HAHYL fusion protein as well as tag free 2-
HAHYL. The MBP- fusion protein was dialyzed into 50 mM Tris, 50 mM NaCl, 10% 
glycerol, 1mM EDTA, 1 mM THP pH 8.0 (buffer A) and further purified using ion-
exchange chromatography. The fusion protein was eluted using linear gradient of NaCl. 
Fractions were pooled together and further purified using superdex-200 using 50 mM 
Tris, 150 mM NaCl, 1mM EDTA, 1 mM THP pH 8.3. MBP-2-HAHYL thus obtained was 
used for crystallization experiments. 
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 For His-MBP cleavage, 1 mg of purified TEVP was added to ~ 40 mg of 2-
HAHYL in the presence of 1 mM THP and incubated at 20 °C for 4 hours.  After 4 hours, 
the TEVP mixed 2-HAHYL was dialyzed overnight into buffer A and again loaded onto 
Ni-IDA column.  Tag free 2-HAHYL was collected either in the flow-through or in 3% 
buffer B. Clean samples (as adjudged by SDS-PAGE) were pooled together and dialyzed 
overnight into 100 mM Tris, 200 mM NaCl, 1 mM EDTA, 5 % glycerol, 1 mM THP pH 
8.0 and further purified using size-exclusion chromatography.  All the dialysis steps were 
performed at 4 °C, unless otherwise stated. 
 
A.4.2 Crystallization of 2-HAH 
 Several attempts to obtain crystals of 2-HAHYL resulted in almost no success. 
These attempts included reductive methylation, modification using iodoacetic acid, in situ 
proteolysis using various commercial available proteases. These results indicated that 2-
HAHYL might be recalcitrant to crystallization therefore,\ we decided to use the following 
approaches: 
1)- Domain dissection of 2-HAHYL: 2-HAHYL is FAD- dependent enzyme and is predicted 
to have multiple domains. To test this hypothesis, we analyzed the protein sequence of 2-
HAHYL using InterPro: protein sequence and analysis tool 
(http://www.ebi.ac.uk/interpro/).  InterPro utilizes diverse source repositories to predict 
domains and important sites in proteins.   Based upon our analysis of 2-HAHYL amino 
acid sequence, we designed 8-394, 5-424, and 1-410 truncation constructs. Unfortunately, 
all the three constructs resulted in insoluble protein. Perhaps, a more comprehensive 
design of construct is warranted to obtain soluble and active protein. 
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2)- Disordered region prediction: Proteins that are recalcitrant to crystallization, 
sometimes harbor very flexible regions. Therefore, we decided to carry out disordered 
region prediction using online tools. All the analysis pointed at making a construct that 
lacks last six amino acids at the C-terminus of the protein. Furthermore, the construct 
obtained from Dr. Sobrado’s laboratory was designed such that MBP was fused to the N-
terminus of the 2-HAHYL. Cleaving the fusion protein sometimes renders an unstable 
target protein. Therefore, we decided to design a construct that does not have MBP as 
fusion partner.  
 To achieve this, we cloned 2HAHYL into pKA8H using NdeI and BamHI sites 
such that the last six amino acids (predicted to be disordered by PrDOS3) were not 
included in the final construct. The truncated construct thus designed was cloned into 
pKA8H using standard methods and several expression tests using autoinduction (LB and 
TB media at 25 °C and 18 °C) and IPTG (ranging from 100 μM to 0.5 mM at 18 °C and 
25 °C) were performed. We were able to express copious amounts of protein but it was 
mostly insoluble. 
3)- Homology screening: In addition to the above-mentioned approaches, we subcloned a 
related 2-HAH from Burkholderia sp. WS (2-HAHWS).  
 We subcloned 2-HAHWS using NdeI and BamHI restriction sites into pKA8H 
vector.  Clone was verified using DNA sequencing and was transformed into BL21(AI) 
(for arabinose-induced autoinduction) and BL21(DE3)pLysS (IPTG based expression). 
Our expression tests concluded that, 2-HAHWS was able to express but was insoluble and 
therefore could not be used for further studies. 
 In parallel, to the above, Dr. Sobrado’s lab cloned 2-HAHWS into pVP56K vector 
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(identical to 2-HAHYL). We transformed the MBP-2-HAHWS construct into 
BL21(DE3)pLysS and protein was expressed using identical method was for 2-HAHYL.  
Briefly, cells were harvested as mentioned for 2-HAHYL and resuspended in 20 mM Tris-
sulfate, 300 mM sodium sulfate, 5 % glycerol pH 7.6 and frozen until further use. 
 Frozen cells were thawed in the presence of 1 mM PMSF, 0.7 % β-octyl 
glucoside (BOG), stirred at 4 °C for 15-20 minutes and ruptured using sonicator. The cell 
debris was separated by centrifugation at 17,000 rpm at 4 °C. The supernatant was loaded 
onto Ni2+ column and protein was purified using identical method as written above for 2-
HAHYL. The fusion protein thus obtained was incubated with TEVP (1mg of TEVP/40 mg 
of MBP-2-HAHWS) in presence of 1 mM THP for three hours at 20 °C and dialyzed 
overnight against buffer A. Next day, MBP-2-HAHWS plus TEVP mixture was loaded 
onto Ni2+ column and tag free 2-HAHWS was collected either in flow through or eluted 
using 3 % of buffer B (Buffer A + 1 M imidazole pH 7.6).  
 Appropriate fractions were pooled together and dialyzed into 75 mM Tris, 50 mM 
Na2SO4, 50 mM glutamic acid, 50 mM L-arginine, 1 mM THP pH 7.6. The dialyzed 
protein was further purified using size- exclusion chromatography (superdex-200 
column) using the same buffer. 
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A.5 Subcloning and expression of Polyphosphate kinase (PPK2) 
 
 
Inorganic polyphosphate, poly P is present in all bacteria, fungi, plants and animals. 
It plays a role in the phosphorylation of nucleoside mono- and di- phosphates. It is 
needed for bacterial survival under stress conditions and for virulence in some 
pathogens1.  
Polyphosphate kinases are the enzymes that catalyze the reversible synthesis of 
inorganic polyphosphate (poly P) from nucleoside di- and tri- phosphates. These can be 
classified as PPK1 and PPK2 depending upon their substrates. PPK1 catalyzes the 
reversible synthesis of poly P from ATP using Mg2+ as the cofactor, whereas, PPK2 uses 
poly P as a donor to synthesize both GTP and ATP from their respective nucleoside 
diphosphates2. Thus, in PPK2 the rate of poly P utilization is 100-fold greater than poly P 
synthesis2a.  
 
A.5.1 Subcloning of PPK2 
 
The FtPPK gene was previously cloned into pET-21 vector. For the expression of 
an N-terminus tagged fusion protein, the gene was then subcloned into pSV281 vector 
using BamHI and XhoI restriction sites. Briefly, the FtPPK gene was amplified using 
PCR to incorporate BamHI and XhoI restriction sites at N- and C-terminus, respectively.  
The PCR product was gel purified (using 0.8% agarose gel and Qiagen PCR clean-
up kit). The purified PCR product was then first ligated into P0 vector at 16 °C overnight. 
The ligation product was then transformed into DH5α cells and plated onto LB agar 
supplemented with 40 μg/ml kanamycin. The plates were incubated overnight and the 
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following day four single colonies were selected and grown overnight at 37 °C and 250 
rpm in LB broth using kanamycin. After plasmid extraction, DNA was digested using 
BamHI and XhoI restriction enzymes and gel purified. The insert thus obtained was 
ligated into pSV281 vector (previously digested using BamHI and XhoI restriction 
enzymes and gel purified). The ligation product was transformed into DH5α, plated onto 
LB agar supplemented with 40 μg/mL Kanamycin and incubated overnight at 37 °C. Four 
single colonies were picked the following day and were grown in LB broth supplemented 
with 40 ug/mL Kanamycin. An analytical 0.8% agarose gel was run to confirm whether 
the gene was incorporated or not. Further, DNA sequencing confirmed the presence of 
FtPPK gene in pSV281 vector.  
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A.6 Subcloning of Bdellovibrio bacteriovorous Proline utilization A 
(BbPutA). 
 
 A synthetic gene encoding PutA from Bdellovibrio bacteriovorus HD100 
(BbPutA, 982 residues, NCBI RefSeq number NP_968157.1) with codons optimized for 
expression in E. coli was purchased from BIO BASIC Inc. (Markham, Ontario CA).  
The gene was obtained in pUC57 vector with NdeI and BamHI sites engineered at N- 
and C- terminus respectively. BbPutA-pUC57 construct was transformed into E. coli 
DH5α and plated on to LB Agar supplemented with ampicillin. The plates were 
incubated at 37 °C in an incubator. The following day a single transformant was used to 
inoculate LB broth media supplemented with 50 μg/mL ampicillin and grown for 
approximately 12 hours at 37 °C/ 250 rpm. Next, the plasmid was extracted using 
manufacturer’s protocol and the resulting plasmid was triple digested using NdeI, 
BamHI and BsaI at 37 °C for 2 hours. BbPutA free of the parent vector was gel purified 
using 1 % agarose and ligated into pKA8H vector (already digested with NdeI/BamHI 
and gel purified). The ligated product was transformed into E. coli DH5α, plated on to 
LB Agar supplemented with 50 μg/mL ampicillin and incubated at 37 °C overnight.  
Following incubation, four single colonies were picked and grown in LB broth 
supplemented with 50 μg/mL ampicillin. The resulting cultures were incubated at 37 °C 
and 250 rpm in an incubator-shaker and further used for plasmid preparation. Finally, 
the construct was verified by DNA sequencing. The full length BbPutA-pKA8H 
construct has N- terminal (His)8 tag, cleavable by tobacco etch virus protease (TEVP). 
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